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Abbreviations 
 
 
 
ADR  adverse drug reaction 
ALT  alanine aminotransferase 
ASAT  aspartate aminotransferase 
AUC  area under the curve 
BW  body weight 
Clhep  hepatic clearance 
Clin  intrinsic hepatic clearance 
Clsys  systemic clearance 
Cmax  maximum concentration 
CYP450 cytochrome P450 isoenzyme 
Eh  hepatic extraction 
ECG  electrocardiogram 
EEG  electroencephalogram 
F  bioavailability 
fu  unbound fraction 
GI  gastrointestinal 
h  hour 
HAV  hepatitis A virus 
HBV  hepatitis B virus 
HCC  hepatocellular carcinoma 
HCV  hepatitis C virus 
HDV  hepatitis D virus 
HEV  hepatitis E virus 
i.v.  intravenous  
INR  international normalized ratio  
Q  blood flow across the liver 
Q0  extrarenal dose fraction 
min  minutes 
MEGX monoethyl glycinexylidine 
NSAID non steroidal anti-inflammatory drugs 
PB  Fraction bound to proteins (protein binding in %) 
PD  pharmacodynamics 
PK  pharmacokinetics 
s  seconds 
SD  standard deviation of the mean 
TDM  therapeutic drug monitoring 
Tmax  time point of Cmax 
t1/ 2  half live  
ULN  upper limit of normal 
Vd  volume of distribution 
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1 Summary 
 
A detailed introduction into the topic was obtained by developing a German-language 
online course named “Dose adjustment in Patients with Liver Disease” for the “Swiss 
Virtual Campus” in collaboration with PNN AG, a spin-off company of the ETH Zurich. 
This was followed by the German-language publication “Dosage Adaptation in 
Patients with Liver Disease” in “Grundlagen der Arzneimitteltherapie”, Documed, 
2005, and an additional German-language online course for pharmacists named 
“Dose Adaptation of Drugs in Patients with Liver Insufficiency” published by PNN AG.  
The documents of these online courses and german publications can be found in the 
electronic appendix on CD-ROM. 
This extensive introduction into the topic was followed by the actual investigational 
thesis. 
 
The aim of the thesis was to define strategies for dose adaptation of drugs in patients 
with liver disease. The main focus was to compare the prediction of the kinetic 
behaviour as estimated using hepatic extraction with kinetic studies performed in 
patients with liver cirrhosis. For this purpose, the antineoplastic drugs and the central 
nervous agents on the market in Switzerland were studied.  
 
In chapter 2 and 3, a general introduction and recommendation of dosing in liver 
disease is given.  
Chapter 4 contains a more detailed description of the online course about dose 
adaptation in liver disease for the Swiss Virtual Campus. 
Chapter 6 contains the results of the literature research for kinetic studies in liver 
disease subdivided into the class of antineoplastic drugs (chapter 6.1) and 
psychotropic drugs (chapter 6.2). For each drug, the pharmacokinetic information 
was collected and drugs were classified according to their bioavailability / hepatic 
extraction in order to predict their kinetic behaviour in patients with decreased liver 
function as illustrated in chapter 3. These predictions were compared with kinetic 
studies in patients with liver disease. Furthermore, both the dose dependent and liver 
specific adverse reactions were listed, the identified kinetic studies in liver disease 
summarized for each drug and specific dosing recommendations given.  
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In conclusion, there are currently not enough data for the safe use of cyctostatics and 
psychotropic drugs in patients with liver disease. There are obvious gaps about the 
kinetic behaviour of drugs in patients with liver disease, in particular concerning data 
about hepatic extraction and kinetic studies of drugs with biliary elimination in 
patients with cholestasis. 
Pharmaceutical companies should be urged to provide kinetic data (especially 
hepatic extraction) needed for the classification of such drugs. Kinetic studies should 
be conducted in patients with impaired liver function for drugs with primarily hepatic 
metabolism, allowing to give quantitative advise for dose adaptation.  
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2 General Introduction 
 
Liver insufficiency describes a partial or complete loss of liver function. Such 
functional deficiencies are mainly the result of “hepatic disease”, a general term 
integrating a set of diverse diseases and symptoms. Hepatic disease may be caused 
by viral, bacterial or parasitic infectious agents, xenobiotics, autoimmune diseases, 
genetic accumulation diseases (e.g. hemochromatosis, Wilson’s disease), enzyme 
birth defects (e.g. α-1 antitrypsin deficiency) or liver stasis due to an obstructed liver 
vein.  
The term “cirrhosis of the liver” for its part describes the shared consequence of such 
chronic liver diseases and becomes manifest in characteristic changes like cell death 
and pathological repair processes resulting in nodular regeneration, fibrosis and the 
generation of portasystemic shunts. Liver disease has general implications for health 
(nutritional and metabolic balance, maintenance of body fluid and electrolyte balance, 
coagulation control). Portasystemic shunts and the restricted metabolic capacity of 
the cirrhotic liver lead to alterations in the pharmacokinetics of predominantly 
hepatically eliminated drugs, which may result in toxically increased blood levels, 
thereby requiring a dose adjustment of these drugs (1, 2). 
 
2.1 Liver anatomy and function 
 
The liver lies in the right upper abdominal cavity, in contact with the diaphragm. In the 
adult, the liver weighs between 1.4 – 1.6 kilograms. It is perfused by 1.5 liter blood 
per minute and requires 20% of the total body oxygen supply for its numerous 
functions. The liver is situated in a strategically important position, since it is not only 
fed with oxygen rich blood by the hepatic artery (Arteria hepatica), but also by the 
portal vein (Vena portae), which carries to the liver the joined venous blood of the 
venous plexuses of all unpaired abdominal viscera such as the stomach, spleen, 
pancreas and intestine (3). 
The two afferent blood vessels are accompanied by the leaving bile ducts (Ducti 
hepatici). The interior anatomy adheres to this trio known as Glisson trias, until the V. 
portae and the A. hepaticae branch out in all directions and discharge together in the 
capillaries hence containing mixed blood. These sinusoids run between the narrow 
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cell rows of hepatocytes, joining in a star formation at the Vena centralis, which 
collects the blood from the sinusoids and drains into the Vena hepatica (4).  
The endothelial tissue of the liver sinusoids is equipped with Kupffer cells which play 
a role in the recycling of red blood cells and the cellular defense of the innate 
immune system. Typically, liver sinusoids do not own a basement membrane. This, 
together with the prominent fenestrae in the endothelium, allows the free flow of 
plasma but not cellular elements (5). The plasma is thus in direct contact with 
hepatocytes in the subendothelial space of Disse. This space is crucial for the 
exchange of material between the sinusoids and the hepatocytes, and may be 
obliterated in liver disease (figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The space of Disse also contains Ito cells which store fat or fat soluble vitamins. Ito 
cells seem to play a major role in the generation of fibrosis and cirrhosis of the liver.  
Figure 2.1 Schematic representation of the relationships between the hepatic 
sinusoid, the space of Disse and hepatocytes in the healthy liver. Top: the anatomy of the 
junction between a hepatic arteriole and the sinusoid in addition to the macroscopic 
relationships. Bottom: the free exchange of fluid and substrate(s) between the sinusoidal 
lumen and the space of Disse (Morgan et al., 1995). 
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The hepatocytes are connected by gap junctions and equipped with microvilli that 
point into the space of Disse with the objective of surface area amplification and 
optimization of exchange. The intercellular space of the hepatocytes is welded 
together by tight junctions to form the canaliculi (Canaliculi biliferi), into which the bile 
product of the hepatocytes is secreted. Where the hepatocytes are intact and the 
junctions tight, no bile reaches the sinusoidal blood (4).  
By way of the hepatic artery (A. hepatica) and the portal vein (V. portae) the liver is 
provided with the required substrates for its numerous synthetic, metabolic and 
secretory functions. In addition, the liver detoxifies both naturally occurring and 
foreign substances (xenobiotics) in the body. For all substances resorbed in the 
gastrointestinal tract, the liver operates as a barrier prior to the systemic circulation, 
and is more or less passable, depending on the chemical characteristics of the 
substance. For substances which directly enter into the systemic circulation, e.g. by 
intravenous application, or which have reached the systemic circulation after the first 
liver passage, the liver – in addition to the kidneys and the lungs – again plays a 
pivotal role in the elimination process (3).  
 
2.2 Liver diseases relevant for drug metabolism 
 
Liver cirrhosis 
 
Cirrhosis often represents the final common pathway of a number of chronic liver 
diseases. The development of cirrhosis is characterized by the appearance of 
fibroblasts and collagen deposition in the liver. This is accompanied by a reduction in 
liver size and in the formation of nodules of regenerated hepatocytes. These 
modifications are associated with - and may be responsible for - a reduction in liver 
blood supply, the presence of intra- and extrahepatic portal-systemic shunting, 
capillarization of the sinusoids (loss of fenestrae in sinusoidal epithelia) and a 
reduction in the number and in the activity of the hepatocytes (1). Loss of functioning 
hepatocellular mass and capacity may lead to jaundice, edema, coagulopathy and a 
variety of metabolic abnormalities which may contribute to alterations in the 
pharmacokinetic behavior of many drugs; fibrosis and distorted vasculature lead to 
portal-hypertension and its sequelae, including gastro-esophageal varices and porto-
systemic shunts. Ascites and hepatic encephalopathy results from both 
General Introduction 
 
18 
hepatocellular insufficiency and portal-hypertension (4, 6). Cirrhosis can alter the 
relationship between serum drug concentration and response. A general principle is 
that the pharmacological response to a drug is a function of its free concentration in 
blood. An increase in the free fraction of some drugs, as a result of a reduced serum 
albumin concentration, is one of the well-known effects of cirrhosis (7). 
 
Alcoholic liver cirrhosis 
 
Alcoholic cirrhosis is the most common type of cirrhosis. With continued alcohol 
intake and destruction of hepatocytes, fibroblasts appear at the site of the injury and 
deposit collagen. With continuing hepatocyte destruction and collagen deposition, the 
liver shrinks in size and acquires a nodular appearance. Alcoholic cirrhosis may be 
clinically silent, and many cases (10 to 40%) are discovered incidentally.  
Although patients with liver cirrhosis may stabilize if drinking is discontinued, over a 
period of years, patients may become emaciated, weak, and chronically jaundiced. 
Ascites and other signs of portal hypertension may become increasingly prominent. 
Progressive renal dysfunction often complicates the terminal phase of the illness (4). 
 
Viral hepatitis 
 
Hepatitis is an inflammatory condition of the liver that is caused by viruses or 
hepatotoxins. Viral hepatitis is a systemic infection affecting the liver predominantly 
which is in almost all cases caused by one of five viral agents: hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), the HBV-associated delta 
agent or hepatitis D virus (HDV) and hepatitis E virus (HEV). Although these agents 
can be distinguished by their molecular and antigenic properties, all types of viral 
hepatitis produce a clinically similar illness. This ranges from asymptomatic and 
unapparent to fulminant and potentially fatal acute infections common to all types, on 
the one hand, and from subclinical persistent infections to rapidly progressive chronic 
liver disease with cirrhosis and even hepatocellular carcinoma (8). Several 
informative studies about the effects of acute viral hepatitis on drug disposition were 
conducted (9-11). A small number of patients were studied during the time when they 
had acute viral hepatitis and subsequently after recovery. The drugs that were 
administered included phenytoin (9), tolbutamide (10), warfarin (11) and lidocaine 
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(12). The most consistent finding was that the plasma protein binding of both 
phenytoin and tolbutamide was reduced during acute hepatitis. No consistent 
changes were observed in warfarin and lidocaine kinetics during acute viral hepatitis. 
The reason for this difference is not clear. In general, drug elimination during acute 
viral hepatitis is either normal or only moderately impaired. Observed changes tend 
to be variable and related to the extent of hepatocellular damage incurring. If the 
acute hepatitis resolved, drug disposition returns to normal. Drug elimination is likely 
to be impaired most significantly in patients who develop chronic hepatitis B virus-
related liver disease, but even then only late in the evolution of this disease (13).  
 
Cholestasis 
 
Cholestasis is the result of impaired hepatobiliary transport of substances and water 
and may be classified as extra- or intra-hepatic. 
Extra-hepatic cholestasis encompasses conditions with physical obstruction of the 
bile ducts, which is usually located outside the liver. In intra-hepatic cholestasis, there 
is no demonstrable obstruction of the major bile ducts. Causes are e.g. drug-induced 
cholestasis or hormones (14). Prolonged cholestasis can lead to biliary cirrhosis; the 
time taken for its development varies from months to years.  
Cholestasis causes the retention in the blood of all substances normally excreted in 
the bile. In patients with cholestasis, the clearance of drugs with predominant biliary 
elimination is reduced, serum bile acids are increased. It appears that drugs 
metabolized by CYP’s may also have a diminished hepatic clearance in patients with 
cholestatic liver disease, potentially needing adjustment of their dose (15-17).
 
2.3 Assessment of liver function 
 
Although there are numerous causes of hepatic injury, it appears that the functional 
consequences are determined more by the extent of the injury than by the cause. At 
this time there is no generally available test that can be used to correlate changes in 
drug absorption and disposition with the degree of hepatic impairment. 
Measurements such as creatinine clearance have been used successfully to adjust 
dosing regimens for drugs eliminated primarily by the kidneys. Similar measures of 
hepatic function have been sought using endogenous substances affected by the 
liver such as bilirubin and albumin, or functional measures such as prothrombin time, 
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or the ability of the liver to eliminate marker substrates such as antipyrine (18), 
indocyanine green (18), monoethylglycine-xylidide (MEGX) (19), and galactose (20). 
Despite extensive efforts, no single measure or group of measures has gained 
widespread clinical use to allow estimation in a given patient of how hepatic 
impairment will affect the pharmacokinetic and/or pharmacodynamic of a drug. The 
primary problem shared by all these test substrates is the considerable intersubject 
variability in their clearance, both in healthy individuals and in patients with liver 
disease, usually leading to considerable overlap between these two groups (21-23). 
Another difficulty is represented by some confounding factors in the interpretation of 
the pharmacokinetic results of CYP-dependent test substrates, such as influence of 
genetics, age, gender, environmental factors and the concomitant administration of 
other drugs that modify the activity of the metabolizing enzymes in the liver (7).  
 
An useful classification scheme that is used most commonly in studies designed to 
formulate drug dosing recommendations for patients with liver disease is the Pugh 
modification of Child’s classification of liver disease severity (Table 2.1) (24). The 
Child-Pugh score is calculated by adding the scores of the five factors and can range 
from 5 to 15. Child-Pugh class is either A (a score of 5 to 6), B (7 to 9), or C (10 and 
above). 
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Table 2.1 Pugh modification of Child’s classification of liver disease severity 
  
Assigned score 
 
 
Assessment parameters 
 
 
1 point 
 
2 points 
 
3 points 
Encephalopathy grade * 
Ascites 
Serum bilirubin, mg/dL 
Serum albumin, g/dL 
Prothrombin time (sec >control) 
  
 
0 
Absent 
1-2 
> 3.5 
1-4 
 
1 or 2 
Slight 
2-3 
2.8-3.5 
4-10 
 
3 or 4 
Moderate 
>3 
< 2.8 
> 10 
 
Classification of clinical severity 
 
Clinical severity 
Total points 
 
Mild 
5-6 
 
Moderate 
7-9 
 
Severe 
>9 
 
 
   
 
* Encephalopathy grade 
 
Grade 0  normal consciousness, personality, neurological examination, 
electroencephalogram 
Grade 1  restless, sleep disturbed, irritable/agitated, tremor, impaired 
handwriting, 5 cps waves 
Grade 2  lethargic, time-disoriented, inappropriate, asterixis, ataxia, slow triphasic 
waves 
Grade 3  somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, 
slower waves 
Grade 4  unrousable coma, no personality/behavior, decerebrate, slow 2-3 cps 
delta activity 
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3 General Recommendation of Dosing in Liver 
Disease 
 
3.1 Drug metabolism and liver disease 
 
Pharmacokinetics 
 
A drug’s portion reaching the systemic circulation denotes the bioavailable fraction of 
a dose. By definition, the bioavailability (F) of an intravenously applied drug equals 1, 
thus 100%, its bioavailable fraction corresponding to the entire dose. If the same 
drug is administered orally, the value of 100% is rarely attained. Generally, the 
bioavailability of an orally administered drug varies between 0-1, thus between 0-
100%. This is due to a set of obstacles an oral dose has to overcome before reaching 
the systemic circulation. Indeed, the liver is not the only obstacle, but represents the 
most dominant one, since dissolution and solubility are already optimized by 
appropriate galenics in most pharmaceutical preparations. The liver’s influence on 
the bioavailability is called “first liver pass effect” or in short “first pass effect” (figure 
3.1)  
 
Bioavailability
• Definition: fraction of drug administered reaching the
systemic circulation
• Significance: dosage of drugs with a high hepatic extraction
Dissolved
drugDrug in
tablet
Undissolved
drug
Non-absorbed
drug
Absorbed
drug Bioavailable
dose fraction
(F)
Loss during
first liver passage
Bioavailability
losses (1-F)
Drug in portal
vein
Contents of stomach
and intestine
Gut wall Liver
Figure 3.1 Effect of liver cirrhosis on the bioavailability of high extraction drugs. After oral 
administration, only a fraction of a drug reaches the systemic circulation. Most of the drug not reaching 
systemic circulation is either not absorbed or metabolized during the first passage across the liver. 
Patients with liver cirrhosis and/or portal hypertension can have intra- and extrahepatic porto-systemic 
shunts, preventing the drugs from reaching the hepatocytes and from being metabolized. Furthermore, 
important drug-metabolizing enzymes have a reduced activity in cirrhotic livers. These are the two main 
factors being responsible for an increase in the bioavailability of high extraction drugs in cirrhotics (Delco 
et al., 2005). 
General Recommendation of Dosing in Liver Disease 
 
24 
The extent of the effect depends on the characteristics of the drug. For our present 
purposes, those drugs with Q0 values < 0.5 can be ignored in terms of liver 
metabolism, some exceptions of which will be discussed later. The Q0 value (the 
extrarenal dose fraction) represents the proportion of a dose not excreted unchanged 
in the urine, thus the proportion of the dose that is metabolized and/or biliary 
excreted. Otherwise, subtracting the Q0 value from 100% (1-Q0) gives the proportion 
of the dose which is excreted unchanged via the kidneys. Highly water-soluble drugs 
hold little Q0 values of < 0.5. They are predominantly excreted unchanged in the 
urine and the liver contributes less than 50% to the elimination of these drugs.  
On the contrary, drugs owning Q0 values > 0.5 are poorly water-soluble and have to 
be transformed into more water-soluble metabolites before their renal or biliar 
excretion. Therefore, the liver contributes more than 50% to the elimination of these 
drugs (25). These drugs thus possess one of the prerequisites for being processed 
during the first liver passage. 
As regards the extent of the first liver pass effect, the drugs with Q0 values > 0.5 can 
be further classified into two groups of drugs: those with high hepatic extraction (Eh) 
and consequently low bioavailability and those drugs with low hepatic extraction 
associated with high bioavailability. In between these two groups lies the group of 
drugs with intermediate hepatic extraction and intermediate bioavailability (figure 3.2) 
(25). It is important to realize, that the problem with high extraction drugs (low 
bioavailability) does not consist primarily in the extensive reduction of the oral dose 
en route to the systemic circulation (this could be countersteered by applying higher 
doses), but in the intra- and interindividual highly variable extent of this reduction, 
resulting in poorly predictable blood levels.  
As for the influence of liver disease on bioavailability, it is now easy to see, that all 
factors reducing the liver’s capacity for hepatic extraction could dramatically and 
potentially toxically increase the bioavailability of normally highly extracted drugs. 
Therefore, the initial dose of orally applied high extraction drugs has to be reduced 
accordingly in the case of liver disease (25). 
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The appearance of the drug in the systemic circulation is immediately followed by the 
elimination process. Again, the influence of liver disease on drug elimination is 
relevant only for drugs with Q0 values > 0.5, since only these kind of drugs are 
predominantly (more than 50% of a dose) metabolized by the liver and/or biliary 
excreted.  
The metabolic capacity of the liver is described by the intrinsic clearance (Cli). The 
intrinsic hepatic clearance means the capacity of the liver to metabolize a certain 
drug without any limitations by the liver blood flow. It indicates the enzyme content of 
the liver. Together with the unbound fraction (fu) and the liver blood flow (Q), the Cli 
determines the hepatic clearance (Clh). The hepatic clearance, for its part, describes 
the blood plasma volume that is cleared per time from poorly water soluble drugs 
through formation of more water soluble metabolites.  
In liver disease, the diminished exchange of materials between blood and 
hepatocytes as well as the reduced metabolic capacity may cause a decrease in 
hepatic clearance. This, in turn, will lead to prolonged elimination half-lives and 
potentially toxic accumulation of the drugs. Therefore, the maintenance dose of 
intravenously and orally applied drugs with Q0 values > 0.5 has to be reduced 
accordingly in the case of liver disease (25). 
.
Figure 3.2  Coherence between hepatic extraction 
and bioavailability (illustrated by PNN AG). 
* if no other loss like e.g. incomplete dissolution 
hepatic extraction 
 
bioavailability 
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Consequences of liver disease on drug kinetics 
 
Chronic liver disease, in particular liver cirrhosis, can modulate many factors 
determining the behavior of drugs in the body. The most important alterations in the 
kinetic behavior of drugs will be discussed in the following sections. 
 
Drug absorption 
Since patients with liver cirrhosis are frequently affected by gastritis and ulcers of the 
upper gastrointestinal tract (26, 27), absorption of orally administered drugs may be 
impaired. However, the amount of drug absorbed is generally not decreased in 
cirrhotic patients (28), but the absorption of orally administered drugs may be delayed 
in this group of patients. Delayed absorption, which is not explained by gastritis or 
ulcers, has for instance been shown for furosemide in cirrhotics (29, 30), but not for 
torasemide, another loop diuretic used in patients with ascites (29). The studies with 
furosemide suggested that impaired gastrointestinal motility may be the mechanism 
for delayed drug absorption in cirrhotic patients. Cirrhotic patients have indeed 
delayed gastric emptying (32, 33), possibly resulting from a decreased action of 
gastrointestinal hormones such as secretin, glucagon, cholecystokinin or motilin (30). 
In agreement with the proposed mechanism leading to this abnormality, prokinetic 
agents can speed up gastric emptying in cirrhotic patients (31, 32). Oral preparations 
coated with an acid resistant film, in particular those with delayed drug release, may 
therefore have a delayed and/or unpredictable onset of action in cirrhotic patients, 
and should be used with caution in this group of patients. 
 
Drug distribution 
In patients with liver cirrhosis who have edema and/or ascites, the volume of 
distribution of hydrophilic drugs is increased. As a consequence, the loading dose of 
hydrophilic drugs may have to be increased in cirrhotic patients, when a rapid action 
is needed (e.g. for beta-lactam antibiotics or for digoxin). Initial dosing of such drugs 
should therefore be performed according to body weight in cirrhotics with ascites. On 
the other hand, an increase in the volume of distribution is associated with an 
increase in the elimination half-life of such drugs (28). A slower elimination velocity in 
cirrhotics with ascites has indeed been demonstrated for furosemide (33, 34) and for 
beta-lactam antibiotics such as ceftazidime or cefprozil (37, 38). However, the 
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influence of edema and/or ascites on the elimination velocity of hydrophilic drugs 
used in this group of patients appears to be small and has therefore usually no 
practical consequences (33). 
 
Drug metabolism 
Fibrosis impedes the flow of blood through the liver, consequently reducing the 
exchange of material between sinusoidal blood and hepatocytes. As a result, 
substances essential for synthesis are not provided adequately and xenobiotics, 
which are supposed to be detoxified by the liver, proceed into the systemic 
circulation. Drugs are likewise less exposed to the liver, which means a reduced drug 
metabolism. For drugs predominantly eliminated by the liver with Q0 values > 0.5, this 
may lead to a reduction of the hepatic clearance, followed by prolonged elimination 
half-lives and the danger of accumulation (2, 25).  
The pathological formation of connective tissue in the space of Disse increases the 
flow resistance in the sinusoids. This may result in portal hypertension and provoke 
the generation of portasystemic shunts, which by-pass the obstructed sinusoids and 
lead the blood from the portal vein directly into the systemic circulation. In this way, 
oral drugs circumvent their metabolism during the first liver passage. For drugs with 
normally high hepatic extraction, this may manifest in an extensive reduction of 
hepatic extraction, which, in turn, may lead to a potentially toxical increase in 
bioavailability if the usual dose is administered (35).  
With the loss of hepatocytes and reorganization of the connective tissue, the liver 
volume shrinks and the amount of well-functioning structures decreases. Such 
damage to the liver reduces the hepatic synthesis of proteins and enzymes. 
Diminished concentrations in metabolizing enzyme systems may reduce the intrinsic 
clearance of a certain drug. CYP P450-dependent systems are more often affected 
than conjugation reactions (36). For drugs with Q0 > 0.5 and a cytochrome-
dependent metabolism, this may cause a decreased hepatic clearance, followed by 
prolonged elimination half-lifes and the potential of accumulation. 
Cirrhosis of the liver is often associated with reduced albumin synthesis (37). For 
drugs that are highly protein bound, the loss of albumin as a binding partner 
increases the free plasma fraction and possibly also the free plasma concentration. 
This allows a higher concentration of the unbound drug to be metabolized by the 
liver, which means that the hepatic clearance remains unchanged or even increases 
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a little, despite reduced intrinsic clearance. Only in the case of drugs with low hepatic 
extraction (Q0 < 0.5) and high albumin binding (>90%), however, might such a 
phenomenon prove clinically significant. 
Liver cirrhosis may be accompanied by ascites (38). Ascites is caused by portal 
hypertension combined with reduced oncotic pressure due to hypalbuminemia. This 
results in an increased pressing out of fluid into the abdominal cavity. Cirrhotic 
changes of the liver may also impair bile excretion, leading to cholestasis. In the latter 
case, components of the bile enter the blood causing jaundice. The agonizing 
pruritus associated with this condition is probably caused by retained endorphins 
and/or bile salts. Decreased bile excretion into the intestine further causes fatty stools 
and malabsorption (e.g. vitamin K deficiency  increased risk of bleeding). In 
addition, cholestasis reduces the activity of drug metabolizing enzymes, hence 
reducing the clearance of predominantly hepatically eliminated and/or biliary excreted 
drugs (15-17). 
Hypalbuminemia is a common consequence of the cirrhotic liver, which, together with 
portal hypotension enhances the formation of ascites, as discussed above. Ascites is 
accompanied by hypovolumenia. On the other side, vasodilatoric endotoxins from the 
intestine reach the systemic circulation in default of clearance by the intact liver and 
cause a dilatation of the arteries. This is answered by an extensive activation of the 
renin-angiotensin axis and the sympathetic nervous system, finally resulting in renal 
vasoconctriction. The ascites-induced hypovolumenia and the activated sympathetic 
nervous system manifest in reduced renal blood circulation and reduced glomerular 
filtration followed by renal insufficiency. For this reason cirrhotics are often afflicted, 
not only with hepatic insufficiency, but also with renal impairment, and show a 
prolonged renal clearance of predominantly renally excreted drugs (38). 
. 
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Conclusion 
 
In conclusion, the decreased blood flow, the reduction in liver volume, the impaired 
exchange of materials between sinusoids and hepatocytes, and damaged metabolic 
enzyme systems are all responsible for the decreased hepatic clearance of 
predominantly hepatically eliminated drugs (Q0 > 0.5) (table 3.1). An adjustment in 
the maintenance dose is therefore required. Furthermore, in the special group of 
predominantly hepatically-eliminated drugs with additional high hepatic extraction, the 
portasystemic shunts cause a reduction of the liver first-pass effect and therefore a 
rise in bioavailability. In this case, not only the maintenance dose, but also the initial 
dose of orally administered drugs has to be adjusted accordingly. 
.
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Table 3.1: Effects of liver cirrhosis on pharmacokinetics 
 
 Changes in 
cirrhosis 
Effect on Clh Effect on Eh 
Hepatic blood flow (Q) ↓ ↓ Ø 
Portasystemic shunts ↑ Ø ↓ 
Liver volume (↓)  Cli ↓ ↓ Ø 
Cytochrome P450 ↓  Cli ↓ ↓ Ø – (↓) 
Albumin synthesis ↓  fu ↑ (↑) Ø 
Cli = intrinsic clearance / Clh = hepatic clearance / Eh = hepatic extraction 
↓ = decreases / ↑ = increases / Ø = unchanged 
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3.2 General recommendation of dosing in liver disease 
 
While renal function can be determined by creatinine clearance (39), there is no 
satisfactory alternative available for the assessment of liver function and capacity. In 
cirrhotics, usually neither the liver blood flow nor the extent of the portasystemic 
shunting is known. While the hepatic blood flow could be estimated by Doppler 
sonography and the bile acid concentration in the serum might indicate the extent of 
the portasystemic shunts (40), it is not clear yet, if this could contribute to the dosing 
in liver cirrhosis. Furthermore, the complexity of the drug metabolizing enzyme 
systems, inter- and intraindividual fluctuations of the hepatic clearance and the 
diversity of affecting factors like genetics, gender, age and environmental factors has 
made impossible the clinical acceptance of a single test substance (table 3.2). 
To date, the risk for clinical relevant drug accumulations has to be estimated for each 
drug individually. This estimation is based on the kinetic properties of the drug, in 
particular the Q0 value and the hepatic extraction Eh of a certain drug. Values for Q0 
values and hepatic extraction rates can partly be looked up in acts like the 
“Arzneimittelkompenidum der Schweiz”, the “Physicians Desk Reference” and 
“Grundlagen der Arzneimitteltherapie” (edition 2005). For new drugs, the regulatory 
authorities require the data of kinetic studies in liver insufficiency. Dosage 
recommendations – as far as available - can be found in “Arzneimittelkompendium 
der Schweiz” or “Physicians Desk Reference” or similar publications.  
In order to use the hepatic extraction Eh for dosage recommendations of 
predominantly hepatically-eliminated drugs (Q0 > 0.5), the term “Eh) has to be 
described mathematically first and pulled together with hepatic clearance Clh and 
liver blood flow Q. For this, equation (1) and (2) are useful: 
 
 
              fu x Cli 
Eh                                                                  (1)
 
           (fu x Cli) + Q 
 
 
Cli: intrinsic clearance 
fu: fraction unbound 
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Q: liver blood flow 
Eh: hepatic extraction rate 
By multiplication of equation (1) by the liver blood flow Q, the equation for hepatic 
clearance Clh results:  
 
 
 
                                    Q x fu x Cli
 
Clh = Eh x Q =                                        (2)
                           
                                   (fu x Cli) + Q 
 
 
 
Hepatic clearance Clh refers to the volume of blood that is cleared by the liver of the 
drug per time unit. 
 
High extraction drugs 
 
High extraction drugs undergo a high extraction during the first passage across the 
liver (≥ 60%, Eh ≥ 0.6), and therefore have a low bioavailability of ≤ 40% (figure 3.2). 
Highly extracted drugs are characterized by a high intrinsic clearance Cli. This 
means, that more enzyme capacity for a certain drug is present than drug is arriving 
by blood flow Q per time. Thus, the value of [fu x Cli] greatly exceeds the value of Q. 
Therefore, the addition of Q in the denominator of equations (1) and (2) can be 
neglected. The equations are reduced to: 
 
Since    (fu x Cli) >> Q,        Eh ≈  1   (3)    and    Clh  ≈  Q    (4) 
 
 
As shown by equation (4), changes in the liver blood flow Q directly influence the 
hepatic clearance Clh, and the hepatic clearance Clh of high extraction drugs mainly 
depends on Q. These drugs are therefore called “flow-limited” or “high extraction”. 
 
Dose adaptation of “high extraction drugs” 
Since the blood flow across the liver is typically decreased in patients with liver 
cirrhosis (41, 42), elimination of high extraction drugs is retarded in comparison to 
patients with normal liver function. In addition to a decreased blood flow across the 
liver, patients with liver cirrhosis frequently have porta-systemic shunts, preventing 
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the exposure of drugs to hepatocytes (28, 43). As a consequence, a variable amount 
of portal blood is not cleared by hepatocytes, potentially leading to a significant 
increase in bioavailability of orally administered high extraction drugs (figure 3.3).  
For example, the bioavailability of clomethiazole is 10% in healthy persons and may 
increase to 100% in patients with liver cirrhosis (44). This increase in bioavailability is 
associated with a 10-fold higher drug exposure, eventually leading to adverse drug 
reactions.  
As a consequence of increased bioavailability, the initial dose of orally administered 
“high extraction” drugs has to be reduced by 50% or more, depending on Eh and the 
therapeutic window of the drug (table 3.4) (25). 
As demonstrated by equation (4), the hepatic clearance Clh depends on the blood 
flow Q across the liver. In liver cirrhosis, blood flow and exchange of materials 
between sinusoids and hepatocytes are impaired which decreases the hepatic 
clearance Clh. This reduction in hepatic clearance is associated with a prolongation of 
elimination half-life and a risk of accumulation, if no dose reduction or prolongation of 
the dosing interval is performed. In patients with liver cirrhosis, not only the initial 
dose, but also the maintenance dose of orally administered “high extraction” drugs 
has to be reduced by 50% or more, depending on Eh and the clinical sings (25).  
In the case of i.v. application, the usual starting dose can be applied, but still the 
maintenance dose has to be adjusted according to hepatic clearance and should be 
reduced by about 50% depending on the drug and the clinical sings (tables 3.4 and 
3.5) (25). 
 
Another approach is to assume a 100% oral bioavailability of such drugs in cirrhotic 
patients. Accordingly, initial and first maintenance doses should be reduced taking 
into account the assumed increase in bioavailability: 
 
   
100
ilitybioavailabdosenormaldoseducedRe ×=  (5) 
 
“Normal dose” is the starting dose in a patient without liver disease and 
“bioavailability” the percentage of a drug ingested orally reaching the systemic 
circulation in a healthy person. The maintenance dose should be adjusted taking into 
account the desired pharmacological effect and toxicity of the drug used (25). Using 
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this approach, a possible reduction in drug clearance due to impaired hepatic blood 
flow is not considered, but may be neglectable compared to the assumed increase in 
bioavailability.  
 
In conclusion, for high extraction drugs administered orally, both initial and 
maintenance doses have to be reduced in patients with liver cirrhosis. The extent of 
this reduction cannot be predicted accurately, however, since neither porta-systemic 
shunts nor hepatic blood flow are usually known in a given patient.  
On the other hand, for high extraction drugs administered intravenously, a normal 
initial dose can be administered and the maintenance doses have to be reduced 
according to hepatic clearance, which is reflected by blood flow across the liver 
(tables 3.4 and 3.5).  
 
 
 
 
 
 
 
 
Figure 3.3  Effect of liver cirrhosis on the kinetics of drugs with high or 
low hepatic extraction. For drugs with a high hepatic extraction, the maximal 
plasma concentration and bioavailability increase, and elimination is 
slowed. For drugs with a low hepatic extraction, only elimination is slowed. 
Accordingly, for drugs with a high hepatic extraction, both initial and 
maintenance dose have to be reduced, whereas for drugs with a low 
hepatic extraction, only the maintenance dose has to be adapted (Delco et 
al., 2005). 
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Substance 
(application) 
E (%) Metabolism Clinical use Ref. 
Serum bile acids 
(endogenous) 
>90 Hydroxylation and conjugation, 
enterohepatic cycling 
May be useful for estimation of portasystemic shunt (43) 
Indocyanine green 
(i.v.) 
90 Biliary excretion Estimation of hepatic blood flow (45) 
Galactose (i.v.) 95 Rate-limiting step is 
phosphorylation 
First-order elimination reflects “functional hepatic capacity”. 
Extrahepatic metabolism is problematic 
(46) 
Sorbitol (i.v.) >80  Estimation of hepatic blood flow (47) 
Lidocaine (i.v.) 80 CYP3A  (48) 
d-Propoxyphene (p.o.) 70 CYP3A Ratio norpropoxyphene/d-propoxyphene may be useful to estimate 
protasystemic shunt 
(49) 
Erythromycin (i.v.) 30 CYP3A CO2 exhalation is used as a marker of CYP3A activity (50) 
Antipyrine (p.o.) 5 Different CYPs Reflects activity of different CYPs (51) 
Aminopyrine (i.v.) <30 Different CYPs CO2 exhalation is used as a marker of general CYP activity (52) 
Caffeine (p.o., i.v.) <30 CYP1A2, N-acetyltransferase 
Type 2 (NAT2) 
CO2 exhalation measures mainly activity of CYP1A2 (53) 
Table 3.2: Substances investigated for quantification of liver function/liver metabolism 
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Low extraction drugs 
 
Predominantly hepatically eliminated drugs (Q0 > 0.5) which are only minimally 
extracted out of the blood during the first liver passage (≤ 30%; Eh < 0.3) and have 
therefore a high bioavailability of ≥ 70%). They are characterized by a low intrinsic 
clearance Cli. Only limited enzyme capacity is present for the metabolism of these 
drugs and the metabolic activity will not change, even if by a change in the liver blood 
flow more or less drug is delivered to the enzymes per time. Thus, the expression [fu 
x Cli] is much smaller than that of the blood flow Q. The addition of [fu x Cli] in the 
denominator of the equations (1) and (2) can therefore be neglected. As a 
consequence, the equations are reduced to:  
 
 
                                                          fu x Cli                      
Since   (fu x Cli) << Q,          Eh ≈                           (6)       and    Clh   ≈  fu x Cli    (7) 
                                                              Q  
      
 
As shown by equation (7), the hepatic clearance Clh depends on the intrinsic 
metabolic capacity Cli of the liver and on the unbound fraction fu of such drug, but is 
resistant to changes in the hepatic blood flow Q. These drugs are therefore called 
“enzyme-limited” or “low-extraction”. 
 
Dose adaptation of “low extraction drugs” 
As shown by equation (7), hepatic clearance Clh does not depend on liver blood flow 
Q. Since the bioavailability of these drugs is already high (per definition ≥ 70%), even 
in the presence of porta-systemic shunts, bioavailability of these drugs will not 
increase significantly. Therefore, therapy can be started with the usual initial dose. 
However, the hepatic clearance Clh of these drugs may be reduced. This reduction in 
hepatic clearance Clh is what high and low extraction drugs have in common (figure 
2). Whereas in high extraction drugs this decrease in hepatic clearance Clh is 
explained by the changes in liver blood circulation (Q is reduced in equation (4)), the 
decreased hepatic clearance Clh of low extraction drugs has to be considered as a 
consequence of reduced enzyme activity (Cli is reduced in equation (7)).  
Therefore, depending on the drug and liver function, the maintenance dose of low 
extraction drugs should be reduced to about 50% of the normal dose. In the case of 
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i.v. application, a similar dose reduction of the maintenance dose is required as for 
orally administered drugs (tables 3.4 and 3.5) (25).  
 
“Low extraction drugs” with high binding to albumin 
Low extraction drugs with a high binding to albumin (>90%) may represent an 
exception from the rule that hepatic clearance is mainly determined by the activity of 
drug metabolizing enzymes (Cli) (figure 3.4). In patients with reduced serum albumin 
concentrations, a frequent finding in patients with liver cirrhosis, the free fraction fu 
(and also the free concentration) of such drugs is increased. Assuming a first order 
reaction (the reaction velocity is proportional to the free drug concentration), such 
drugs may be metabolized more rapidly in cirrhotic patients. According to equation 7, 
Clh of such drugs may therefore remain unchanged or may even be increased in 
cirrhotics. 
Importantly, the total plasma concentration of such drugs is decreased when their 
free concentration is in the normal range. In order to avoid toxicity by overdosing, 
free drug levels should be determined and used to guide therapy of such drugs, e.g. 
for phenytoin or valproate. 
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Figure 3.4.  Effect of the serum albumin concentration on the total serum concentration 
and free fraction of drugs with high albumin binding. The free concentration of a drug with high 
binding to albumin (≥90% at a normal serum albumin concentration) is kept constant at 10. 
Under normal conditions (normal serum albumin, binding capacity 100%), 90% of the drug is 
albumin-bound and 10% is free. The total plasma concentration is 100. When the serum 
albumin concentration is lowered by one third (binding capacity 67%), the free concentration 
remains 10. The free fraction increases to 14% and the total serum concentration decreases 
to 70. After lowering the serum albumin concentration to 33% of normal (binding capacity 
33%), the free concentration remains 10, the free fraction increases to 25% and the total 
serum concentration of the drug drops to 40. When the free fraction of a drug is above normal, 
the reason for this finding should be sought and the free drug concentration should be used 
for therapeutic drug monitoring (Delco et al., 2005). 
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Intermediate extraction drugs 
 
The hepatic clearance of drugs with a hepatic extraction Eh between 30% and 60% 
(”intermediate extraction drugs”) is determined by both liver blood flow Q and intrinsic 
clearance Cli. The kinetic behavior of these drugs lies somewhere between that one 
of “high” and “low extraction drugs”. 
 
Dose adaptation of “intermediate extraction drugs” 
The hepatic clearance of these drugs is influenced by both liver blood flow Q and 
intrinsic clearance Cli, which are both decreased in patients with liver cirrhosis. 
However, since bioavailability of these drugs is 40% or more, the influence of porto-
systemic shunts is less pronounced as compared to “high extraction” drugs. In 
general, the hepatic clearance Clh of these drugs is reduced, necessitating 
adjustment of their maintenance dose. Treatment should be started with an oral 
initial dose in the low range of normal. In the case of i.v. application, therapy can 
be started with the normal dose. In both applications, the maintenance doses 
should be reduced to about 50%, depending on the specific drug and liver function 
(tables 3.4 and 3.5) (25).  
 
 
Problems in classification of drugs according to hepatic extraction 
 
Values for hepatic extraction Eh are published only for a minority of drugs. Eh has 
therefore to be estimated based on the bioavailability or by using the following 
equation (derived from equation 1 and from the definition of Q0): 
 
      Q
ClQ
E sys0
×
=     (8) 
 
Q0 is the fraction of a drug metabolized by the liver (Clhep = Q0 x Clsys), Clsys the 
systemic clearance of this drug and Q liver blood flow. The values for Q0 and for Clsys 
can be obtained from different sources (54-56). 
Both approaches, using oral bioavailability as a surrogate for hepatic extraction or 
calculation of hepatic extraction using equation (8), have their limitations. Oral 
bioavailability can be less than 100% not only due to a first liver pass effect but also 
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due to incomplete dissolution of tablets in the gut, incomplete absorption in the gut 
and/or degradation in the enterocytes (figure 3.2). Enterocytes contain CYP3A4, 
which can metabolize CYP3A4 substrates such as midazolam (57) or cyclosporine 
(58), before they reach the liver. They also contain P-glycoprotein, which can 
transport drugs from the enterocytes back to the lumen of the intestine, as shown for 
digoxin (59). On the other hand, oral bioavailability can be measured directly in 
humans, which is difficult for hepatic extraction. A weakness of the calculation of 
hepatic extraction using equation 8 is that the systemic clearance of a drug is 
measured usually in plasma and not in blood. For substances with a different 
concentration in plasma and in erythrocytes (e.g. drugs which are trapped in 
erythrocytes such as ribavirin), the results of this approach will therefore be wrong. In 
our studies, we therefore used both approaches and detected an acceptable 
agreement between them (60). 
 
 
Impact of liver disease on hepatic enzyme systems 
 
Studies assessing the protein content and/or the activity of important drug 
metabolizing enzymes (cytochrome P450 isoenzymes and conjugation reactions) in 
livers from cirrhotic patients show that enzyme activities and protein content are 
reduced with increasing disease severity as expressed by the Child score, but with a 
large interindividual variability (61-63). 
The reduction in Cli associated with liver cirrhosis appears not only to be a function of 
the Child score, but also of the metabolic reaction involved (figure 3.5). Conjugation 
reactions such as glycosylation and transfer of sulfate groups (phase II reactions) are 
considered to be affected to a lesser extent by liver cirrhosis than cytochrome P450 
(CYP)-associated reactions (phase I reactions) (28). For instance, the clearance of 
oxazepam (64) or temazepam (65), two benzodiazepines which are only conjugated, 
are not reduced in patients with liver cirrhosis, whereas the clearance of diazepam 
(70, 71) or midazolam (66), both undergoing phase I and phase II reactions, is 
decreased. As discussed above, the decrease in CYP activity and/or protein content 
is highly variable in cirrhotic patients (61, 63, 67-70). This variability can be explained 
by the different mechanisms affecting CYP activity and/or protein content, such as 
impaired transcription for CYP 1A, 3A and 2C (73, 76), altered post-translational 
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modification for CYP 2E1 (67) or increased sensitivity to cholestasis as described for 
CYP 2E1 and 2C9 (61, 67). 
Several studies have shown that also conjugation reactions can be impaired. 
Reduced glucuronidation has been demonstrated for zidovudine (71, 72), diflunisal 
(73), morphine (80, 81), mycophenolate (74), lormetazepam (75) and lamotrigin (76). 
The activity of sulfotransferases was also found to be reduced, whereas sulfatase 
activity appears to be spared (62). 
Despite the finding that conjugation reactions are also impaired in cirrhotic patients, it 
appears to be justified to recommend preferentially drugs which are mainly 
eliminated by conjugation, since only one metabolic pathway is involved. If no studies 
are available, we recommend using a maintenance dose of 50% of normal in patients 
with Child class A and of 25% in patients of Child class B and to adjust this dose 
according to the pharmacological effect and toxicity. For Child class C patients, it is 
recommended to use drugs whose kinetics is not affected by liver disease or for 
which therapeutic drug monitoring is available (25). 
 
 
 
Figure 3.5 Schematic diagram showing the effects of various stages of liver disease severity 
on the intrinsic clearance of drugs mediated by representative metabolic pathways. Estimates for 
glucuronidation (Hasselström et al., 1990), CYP2D6 (Adedoyin et al., 1998), CYP3A4 (Testa et al., 
1997) and CYP2C19 (Adedoyin et al., 1998) pathways are based on the literature sources 
indicated in parentheses.  
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Dose adaptation in cholestasis 
 
As mentioned in a preceding section, cholestasis impairs the activity of several 
CYPs, for instance CYP2C (67) and 2E1 (61). In patients with cholestasis, drugs 
which are metabolized by CYPs can therefore have a diminished hepatic clearance, 
potentially needing adjustment of their dose. 
While it is conceivable that drugs with predominant biliary elimination may have a 
decreased clearance in patients with cholestasis, it is surprising that kinetic studies 
exist for only few of such drugs. As discussed, kinetics and dynamics have been 
investigated in cholestatic patients particularly for antineoplastic agents, among them 
vinca alkaloids (77, 78), doxorubicin and derivatives (79-81) and dactinomycin (82). 
These studies resulted in recommendations for dose adjustment according to the 
serum bilirubin concentration and/or activity of alkaline phosphatase (82). It remains 
unclear, however, whether these two parameters are the best markers for dose 
adjustment in cholestasis or whether other enzyme activities and/or the serum bile 
acid concentration would be more accurate. Considering the impact of cholestasis on 
kinetics and dynamics of antineoplastic drugs (83), it is crucial that kinetic studies in 
cholestatic patients are performed also with other drugs exhibiting a predominant 
biliary excretion and/or enterohepatic cycling, e.g. phenprocoumon, mycophenolate 
and others. 
 
 
Dose adaptation of predominantly renally excreted drugs 
 
It is well established that cirrhotics have reduced effective renal plasma flow and 
glomerular filtration rates, also in the absence of ascites (84-86). On the other hand, 
several studies have shown that patients with liver cirrhosis tend to have low serum 
creatinine concentrations (87-89), indicating that glomerular filtration rates cannot be 
estimated using the serum creatinine concentration. The low serum creatinine 
concentration in cirrhotics can be explained by impaired synthesis of creatine and a 
reduced skeletal muscle mass (89). For the same reasons, calculation of the 
creatinine clearance using the Cockcroft formula (90) may overestimate glomerular 
filtration (99-101). Theoretically, the determination of the creatinine clearance based 
on urinary excretion of creatinine should yield accurate results, even in patients with 
impaired creatine synthesis and/or reduced muscular mass. While one study has 
General Recommendation of Dosing in Liver Disease 
 
43 
shown that the measured creatinine clearance reflects glomerular filtration in 
cirrhosis accurately (91), other studies indicate that glomerular filtration is 
overestimated, in particular in patients with reduced glomerular filtration rates (88, 
92-94). This finding has been explained by an increased secretion of creatinine in 
cirrhotics (89, 95). The serum cystatin C concentration, another endogenous marker 
for renal function, may reflect glomerular filtration more accurately in cirrhotic patients 
(88). 
Since the glomerular filtration rate is usually decreased in patients with liver cirrhosis, 
also drugs with mainly renal elimination and a narrow therapeutic range should be 
dosed with caution in this group of patients. A decreased renal elimination in cirrhotic 
patients has been shown for several drugs, among them cefpiramide (96), cilazapril 
(97), fluconazole (98), lithium (99, 100) and ofloxazin (101, 102). 
Interestingly, in patients with renal failure, CYP-associated drug metabolism has 
been shown to decrease (103), in particular for CYP 2D6. Similar observations have 
been reported for rats, where several CYPs show a reduced expression (104). The 
clinical relevance of these findings has been demonstrated among others for 
metoclopramide, which reveals an over-proportional reduction in total body clearance 
in patients with renal failure (105). 
 
 
Pharmacodynamic alterations in liver disease 
 
Patients with liver cirrhosis have been reported to be more sensitive to central 
adverse effects of morphine (106, 107) and benzodiazepines (108, 109), and to renal 
adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) (110), whereas the 
sensitivity to the natriuretic effect of loop diuretics was found to be reduced (28). 
An early study described precipitation of hepatic encephalopathy after intravenous 
administration of morphine in patients with decompensated liver cirrhosis at low 
doses (8 mg i.v.) (106). In contrast, in a more recent study, none of 6 cirrhotics 
developed encephalopathy after i.v. administration of higher doses of morphine 
(111). Since several studies have shown that the oral bioavailability of morphine is 
increased and its elimination is impaired (112-114), morphine should be used with 
caution in cirrhotics, irrespective of the presence of an increased sensitivity to central 
adverse effects. 
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Patients with liver cirrhosis appear to be extremely sensitive to the sedative effects of 
benzodiazepines (108, 109). In cirrhotics, benzodiazepines may induce 
encephalopathy which can be reversed by the administration of benzodiazepine 
antagonists (115). While impaired hepatic metabolism has been demonstrated in 
cirrhotics for midazolam (108) and diazepam (109, 116-118), no such changes were 
detected for oxazepam (64), temazepam (65) or triazolam (119), suggesting that 
increased sedation of benzodiazepines in cirrhotics is partially due to 
pharmacodynamic alterations. 
Despite their disadvantages, benzodiazepines are difficult to replace as sedatives in 
cirrhotic patients. Neuroleptics undergo extensive hepatic metabolism and can also 
precipitate encephalopathy. Contrary to the benzodiazepines, they have the 
disadvantage that they cannot be antagonized. Clomethiazole, a sedative used 
widely for the prevention of delirium tremens in Europe, has a high first liver pass 
effect with an unpredictable oral bioavailability in cirrhotics (table 3.5).  
As illustrated in the first section of this article, an unexpectedly high bioavailability 
can result in toxic drug levels with life-threatening respiratory depression. 
Considering benzodiazepines, substances with a long half-life should be avoided, 
and those eliminated by conjugation only, e.g. oxazepam or lorazepam, should be 
preferred. 
In comparison to healthy individuals, a higher tubular concentration of diuretics is 
needed in cirrhotics to excrete a given amount of sodium. This has been shown for 
the loop diuretics torasemide (125, 126), bumetanide (120) and furosemide (121-
123). For torasemide, a diuretic metabolized by the liver, the kidney compensates for 
reduced hepatic metabolism in cirrhotics. A larger amount of drug is therefore 
eliminated by the kidney, leading to an apparently normal pharmacological effect in 
cirrhotics (124). 
NSAIDs are known to precipitate renal failure in patients with cirrhosis and ascites 
(110). Patients with portal hypertension have a low peripheral resistance and 
hyperdynamic circulation due to increased production of vasodilating substances 
such as nitric oxide (125). In order to prevent a large drop in the arterial pressure, the 
renin angiotensin aldosterone and the sympathetic nervous system are activated, 
leading to renal arterial vasoconstriction. For the maintenance of a sufficient filtration 
pressure, local production of vasodilatory prostaglandins is necessary for dilating the 
renal arteries. After ingestion of NSAIDs, renal production of prostaglandins is 
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abolished, eventually leading to renal failure in cirrhotics. Although no clinical data 
have been published for selective cyclooxygenase 2-inhibitors, it has to be assumed 
that they induce similar effects, as suggested by the impaired renal perfusion 
associated with the ingestion of celecoxib by salt-depleted normal subjects (126). 
 
 
Liver disease and adverse effects of drugs 
 
Dose adaptation in patients with liver disease aims at reducing dose-dependent 
adverse effects of drugs (type A reactions). In contrast to type A reactions, adverse 
drug reactions independent of the dose (idiosyncratic or type B reactions) may not be 
avoidable by dose reduction. 
Considering systemic adverse effects, the usefulness of dose adaptation in patients 
with liver disease is most clearly evident for antineoplastic agents, which are often 
associated with dose-dependent, systemic adverse effects. For some of them, as 
discussed above, recommendations for dose adaptation in patients with liver disease 
have been established (82, 83).  
Regarding adverse effects affecting the liver itself, most such events are type B 
reactions (127). Only few drugs reveal a dose-dependent hepatic toxicity, among 
them methotrexate (128), acetaminophen (134, 135) and isoniazid (136, 137). 
Patients with preexisting liver disease, in particular alcoholics, who are treated with 
on of these drugs may therefore be at a higher risk for hepatic toxicity. For 
methotrexate, the mechanism for increased toxicity in alcoholics is not completely 
clarified, but may be due to the presence of two different mechanisms associated 
with liver fibrosis and possibly cirrhosis (128). For acetaminophen, an important 
factor is induction of CYP2E1 by alcohol, increasing the generation of N-acetyl-p-
benzoquinone imine, a toxic metabolite (134, 135). For isoniazid, both preexisting 
liver cirrhosis and ingestion of too much alcohol appear to be risk factors for hepatic 
toxicity (129, 130). Since isoniazid is metabolized also by CYP2E1, increased hepatic 
toxicity in alcoholics may be due to induction of CYP2E1 by alcohol. 
The occurrence of hepatic microvesicular steatosis associated with the ingestion of 
drugs is a typical type B reaction. Microvesicular steatosis is a life-threatening 
condition caused by impaired β-oxidation of liver mitochondria (138, 139) and has 
been described in patients treated with valproic acid (131), analgetic doses of aspirin 
(131), certain opiates (132) or the uricosuricum benzbromarone (133). Since 
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microvesicular steatosis is considered to be more frequent in patients with a 
preexisting mitochondrial disorder, e.g. a defect in β-oxidation or in the urea cycle, or 
a mitochondrial cytopathy (134), certain preexisting liver diseases may also be risk 
factors for type B reactions. 
 
Conclusion 
 
The most dangerous drugs in patients with liver cirrhosis are those with a low 
bioavailability and a narrow therapeutic range when administered orally. For these 
drugs, both initial and maintenance doses have to be reduced by 50% or more of the 
normal dose, depending on the severity of liver disease, hepatic extraction and 
metabolism, and toxicity of the drug. For most other drugs metabolized by the liver, 
only the maintenance dose has to be adjusted. It is important to realize that renal 
function can be impaired in cirrhotic patients despite normal serum creatinine. If no 
immediate pharmacological effect is needed, drug therapy should be started 
cautiously in this group of patients and titrated individually until the desired 
pharmacological effect is achieved or toxicity appears.  
The predictions for dose adaptation remain general and cannot replace accurate 
clinical monitoring of patients with liver disease treated with drugs owing a narrow 
therapeutic range. 
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Table 3.4 Adaptation of the drug dosage in patients with liver disease according to excretion,    
metabolism and hepatic extraction (if no studies available).  
 
Application 
mode Influenced parameter Dosage recommendation 
p.o. 
• Hepatic extraction Eh →  
bioavailability F → 
• hepatic clearance Clh ↓ 
 
• initial dose: normal 
 
• maintenance dose: Dose 
reduction to about 50% of the 
normal dose depending on 
clinical signs; cautious up-
titration.  low  
extraction drugs 
i.v 
 
 
• hepatic clearance Clh ↓ 
• initial dose: normal 
 
• maintenance dose: Dose 
reduction to about 50% of the 
normal dose depending on 
clinical signs; cautious up-
titration. 
p.o. 
• hepatic extraction Eh ↓  
bioavailability F ↑ 
 
• hepatic clearance Clh ↓ 
 
• initial dose: Choose dosage in 
the lower range of normal 
 
• maintenance dose: Dose 
reduction to about 50% of the 
normal dose depending on 
clinical signs; cautious up-
titration. intermediate extraction drugs 
i.v. 
 
 
• hepatic clearance Clh ↓ 
• initial dose: normal 
 
• maintenance dose: Dose 
reduction to about 50% of the 
normal dose depending on 
clinical signs; cautious up-
titration. 
p.o. 
• hepatic extraction Eh ↓   
bioavailability F ↑ 
 
 
 
• hepatic clearance Clh ↓ 
 
• initial dose: Dose reduction to 
about 50% or less of the 
normal dose depending on Eh / 
F and therapeutic range.  
 
• Maintenance dose: Dose 
reduction to about 50% or less 
of the normal dose depending 
on clinical signs; cautious up-
titration or further dose 
reduction. 
high  
extraction drugs 
i.v. 
 
 
• hepatic clearance Clh ↓ 
• Initialdosis: normal 
 
• maintenance dose: Dose 
reduction to about 50% of the 
normal dose depending on 
clinical signs; cautious up-
titration or further dose 
reduction. 
p.o. 
 
In patients with cholestasis:  Clh ↓, 
→,  or ↑ 
• Dose reduction according to 
serum bilirubin concentration 
and/or activity of alkaline 
phosphatase (quidelines exist 
only for some antineoplastic 
drugs) 
 
 
 
 
 
Drugs with significant 
biliar elimination 
(≥5%) 
i.v 
 
In patients with cholestasis:  Clh ↓, 
→,  or ↑ 
• Dose reduction according to 
serum bilirubin concentration 
and/or activity of alkaline 
phosphatase (quidelines exist 
only for some antineoplastic 
drugs) 
Legend: ↑ =increases  / ↓ = decreases /  → = unchanged 
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Table 3.5 Classification of drugs metabolized by the liver according to pharmacokinetic characteristics  
Hepatic 
extraction (E) 
Effect of porto-
systemic shunts on 
bioavailability 
Examples of drugs 
 
 
Low extraction/low protein binding(<90%) 
 
<0.30 
 
not relevant 
Benzodiazepines: alprazolam, bromazepam, clobazam, flunitrazepam, flurazepam, nitrazepam, 
triazolam; Other hypnotics and sedatives: methaqualone, zopiclone; Antidepressants: citalopram, 
fluoxetine, fluvoxamine, moclobemide; Antipsychotics: risperidone; Antiepileptics: carbamazepine, 
ethosuximide, lamotrigine, levetiracetam, phenobarbital, primidone, topiramate; Anti-Parkinson 
drugs: pramipexole; Antineoplastic and immunosuppressive agents: cyclophosphamide, 
hydroxycarbamide, letrozol, melphalane, temozolomide; Antibacterial drugs: doxycycline, 
metronidazole; Tuberculostatic drugs: isoniazid; Corticosteroids: methylprednisone, prednisone; 
Analgesics: paracetamol; Bronchodilators: theophylline; Antihistamines: diphenhydramine; 
Antiemetics: metoclopramide 
 
Low extraction/high protein binding(>90%)  
 
 
<0.30 
 
 
 
 
 
 
 
not relevant 
 
 
Benzodiazepines: chlordiazepoxide, diazepam, lorazepam, oxazepam, temazepam; Other 
hypnotics and sedatives: zolpidem; Antidepressants: maprotiline, trazodone; Antipsychotics: 
sertindole; Antiepileptics: phenytoin, tiagabine, valproate; Anti-Parkinson drugs: tolcapone; 
Analgesics: methadone; Antineoplastic and immunosuppressive agents: chlorambucil, 
mycophenolate; Antibacterial drugs: ceftriaxone, clarithromycin, clindamycin; Tuberculostatic  
drugs: rifampicin; Corticosteroids: prednisolone; Antidiabetic drugs: glipizide, tolbutamide; 
Antihyperlipidemic drugs: clofibrate, gemfibrozil; Antiulcer drugs: lansoprazole; Anticoagulants: 
phenprocoumon; Antiestrogens: tamoxifen, toremifen; Antiandrogens: Cyproterone 
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Hepatic 
extraction (E) 
Effect of porto-
systemic shunts on 
bioavailability 
Examples of drugs 
 
 
Intermediate extraction 
 
 
0.30 - 0.60 
 
may be clinically  
relevant 
Benzodiazepines: midazolam (0.31); Antidepressants: amitriptyline (0.6), clomipramine (0.5), 
mirtazapin (0.43), nortriptyline (0.34), paroxetine (0.38); Antipsychotics: amisulpride (0.52), 
clozapine (0.45), fluphenazine (0.47), haloperidol (0.55), olanzapine (0.4), zuclopenthixol (0.51); 
Psychostimulants: methylphenidate (0.54); Anti-Parkinson drugs: entacapone (0.48); Analgesics: 
codeine (0.52); Antineoplastic and immunosuppressive agents: azathioprin (0.4), etoposide (0.48); 
Antibacterial drugs: ciprofloxacin (0.4), erythromycin (0.38); Antifungal agents: itraconazole (0.4); 
Antiarrhythmics and anesthetic agents: Amiodarone (0.54), lidocaine (0.4); Beta-adrenergic 
blockers: carvedilol (0.41); Calcium channel blockers: diltiazem (0.55), felodipine (0.56), nifedipine 
(0.33); Antihyperlipidemic drugs: atorvastatin (0.55), pravastatin (0.32), simvastatin (0.35); );  
Antiulcer drugs: omeprazole (0.35), ranitidine (0.48); Progestogens: medroxyprogesterone (0.55); 
Prolactine inhibitors: lisuride (0.53); 
 
High extraction 
 
 
>0.60 
 
clinically relevant 
Hypnosedatives, antianxiety drugs: buspirone (0.96), clomethiazol (0.9), zaleplon (0.73); 
Antidepressants: dibenzepine (0.75), doxepin (0.72), imipramine (0.61), mianserine (0.67), 
sertraline (1), trimipramine (0.67), venlafaxine (0.73); Antipsychotics: chlorpromazine (0.68), 
chlorprothixen (n/a), flupenthixol (n/a), quetiapin (0.91), perphenazine (0.8), sulpiride (n/a); 
Anticholinesterases: tacrine (n/a); Anti-Parkinson drugs: bromocriptine (0.60), levodopa (n/a), 
selegiline (1), biperiden (n/a); Analgesics: morphine (0.76), pentazocine (0.8), propoxyphene (n/a); 
Antineoplastic and immunosuppressive agents: ciclosporine (0.72), fluorouracil (0.71), idarubicin 
(1), mercaptopurine (0.80), sirolimus (n/a), tacrolimus (0.75), vinorelbine (n/a); Beta-adrenergic 
blockers: labetolol (n/a), metoprolol (0.67), propranolol (0.75); Calcium channel blockers: 
nicardipine (0.82), verapamil (0.70); Antianginal agents: isosorbide dinitrate (0.78), nitroglycerine 
(1); Antihyperlipidemic drugs: fluvastatin (0.71), lovastatin (0.95); Prokinetic drugs: cisapride (0.65); 
Antimigraine agents: sumatriptan (0.82); Antihelmintics: praziquantel (n/a); Antihistamines: 
promethazine (0.76); Phosphodiesterase inihibitors: sildenafil (0.62) 
 
 
In brackets are the values for hepatic extraction (E), calculated as described in equation (5), or as estimated from bioavailability;  n/a: value not available. 
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4 Online course for the Swiss Virtual Campus 
 
In collaboration with PNN AG (Nicolas Furrer, business data processing specialist, Karin 
Lattmann, webmaster), a German-language online course named “Dose Adaptation in 
Liver Insufficiency” was developed for the Swiss Virtual Campus (www.virtualcampus.ch). 
The course included topics such as anatomy and function of the liver, drug metabolism in 
liver disease, dose adaptation in liver disease and altered pharmacokinetics in liver 
disease. 
This interactive online course was richly illustrated by graphics, tables, pictures and 
stereoscopic structures of drugs. The student’s learning success was verified by 23 
multiple-choice questions. For each true or false answer an explanatory commentary was 
provided.  
The PDF file of this online course is enclosed in the electronical appendix on CD-ROM. 
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5 Aim of the Thesis 
 
In renal dysfunction, the creatinine clearance provides an excellent tool for the estimation 
of renal function upon which dosage recommendations in renal insufficiency can be based. 
Unfortunately, no such marker or clinically useful test system exists so far for dosage 
recommendations in liver disease. The major goal of this project was to define strategies 
for dosage adaptation of drugs in patients with liver disease.  
 
In order to contribute to this field of research, the following was to be elaborated during this 
thesis: 
 
To provide 
 
Guidelines for dose reduction in patients with liver disease (especially 
cirrhosis) for  
 
-  antineoplastic drugs 
- psychotropic drugs  
 
with significant hepatic metabolism and / or biliar excretion available on the market in 
Switzerland. 
 
Where available, the dosage recommendation should be based on kinetic studies in these 
patients. Where such studies are missing, the recommendation should be based on the 
handling of the drug by the liver, which would be predicted by the hepatic extraction rate 
(or bioavailability if missing) of the drug. At the same time, these predictions based on 
hepatic extraction rates or bioavailability should be compared with the results from kinetic 
studies in liver patients.  
 
By this means, a considerable list of drugs including their pharmacokinetic data, both dose 
dependent and liver specific adverse reactions, summarized results of kinetic studies in 
liver patients and individual dosage recommendations in liver disease would be generated. 
These data could be further proceeded to a reference book or electronic database as a 
tool for dosage recommendations in liver disease. 
  54
 
Antineoplastic Drugs 
 55
6 Dose Adaptation in Patients with Liver Disease 
 
 
 
 
 
6.1 Dose Adaptation of Antineoplastic Drugs in Patients with 
Liver Disease 
 
 
The paper has been published in: Drug Safety 2006; 29 (6): 509-522 (see below). 
 
 
A complete list of the investigated antineoplastic drugs can be found in the electronic 
appendix on CD-ROM.
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Summary 
Dose adaptation for liver disease is important in patients treated with antineoplastic 
drugs due to the high prevalence of impaired liver function in this population and the 
dose-dependent, frequently serious adverse effects of these drugs. We classified the 
antineoplastic drugs marketed in Switzerland by the end of the year 2004 according 
to their bioavailability/hepatic extraction in order to predict their kinetic behavior in 
patients with decreased liver function. This prediction was compared with kinetic 
studies carried out with these drugs in patients with liver disease. The studies were 
identified by a structured, computer-based literature search. 
Of the 69 drugs identified, 52 had a predominant extrarenal (in most cases hepatic) 
metabolism and/or excretion. For 49 drugs, hepatic extraction could be calculated 
and/or bioavailability was available, allowing classification according to hepatic 
extraction. For 18 drugs, kinetic studies have been reported in patients with impaired 
liver function, with the findings generally resulting in quantitative recommendations 
for adaptation of the dosage. In particular, recommendations are precise for 13 drugs 
excreted by the bile (e.g. doxorubicin and derivatives, and vinca alkaloids). Validation 
studies comparing such recommendations with kinetics and/or dynamics of 
antineoplastic drugs in patients with decreased liver function have not been 
published. 
We conclude that there are currently not enough data for safe use of cytostatics in 
patients with liver disease. Pharmaceutical companies should be urged to provide 
kinetic data (especially hepatic extraction) used for classification of such drugs and to 
conduct kinetic studies for drugs with primarily hepatic metabolism in patients with 
impaired liver function allowing to give quantitative advise for dose adaptation. 
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Introduction 
Dose adaptation for patients with liver disease is more difficult to perform than for 
patients with impaired renal function. The main reason for this statement is the fact 
that, unlike the creatinine clearance for the kidney, there is no in vivo surrogate to 
predict hepatic drug clearance. Due to the lack of such in vivo markers, predictions 
concerning dose adaptation in patients with liver disease can only be made based on 
the kinetic properties of the drugs to be administered and on kinetic studies of such 
drugs in patients with liver disease (Delco 2005). 
Several reviews have covered this subject during the last years (135-139) (Delco 
2005). In these reviews, drugs are listed according hepatic extraction (E), which is an 
important determinant of hepatic clearance of drugs. The hepatic clearance (Clhep) of 
a drug can be expressed as: 
 
Q)Cl(f
Q)Cl(fQECl
iu
iu
hep +×
××
=×=    (1) 
 
where Q is the blood flow across the liver, and fu the unbound fraction and Cli the 
intrinsic clearance of a drug. Cli represents the maximal capacity of the liver to 
metabolize a given drug, not taking into account limitations by liver perfusion (140). 
Cli can therefore reach values which are larger than Q. 
The basis of the classifications used can best be understood by considering the 
extremes of equation (1), namely (fu x Cli) >> Q or Q >> (fu x Cli). When (fu x Cli) >> 
Q, the denominator in equation (1) simplifies to (fu x Cli), and Clhep equals: 
 
QClhep =  (2) 
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For such drugs, the liver has a very large metabolic capacity, hepatic extraction (E) is 
approaching 1 and the blood flow across the liver becomes rate-limiting for hepatic 
clearance. Such drugs are therefore called “flow-limited”, “high capacity”, “high 
clearance” or “high extraction”. Due to the high hepatic extraction, they have a low 
bioavailability. Since portal blood flow can be decreased in patients with liver 
cirrhosis or patients with multiple metastases (141, 142), hepatic clearance of such 
drugs is decreased in these situations, possibly necessitating a reduction of the 
maintenance dose. A second potential problem of such drugs is an increase in their 
bioavailability in patients with porto-systemic shunts. Porto-systemic shunts are 
usually present in patients with portal hypertension due to liver cirrhosis or fibrosis or, 
of importance in patients with cancer, in patients with multiple metastases (143, 144). 
Therefore, when such drugs are administered orally in patients with portal 
hypertension, the initial and the maintenance doses have to be reduced according to 
the expected increase in bioavailability and to the decrease in hepatic blood flow. For 
intravenous administration, only the maintenance dose has to be reduced according 
to hepatic blood flow. A list of such drugs is given in a recent publication (Delco 
2005). 
For the second type of drugs, Q >> (fu x Cli), the metabolic capacity of the liver is 
much lower than blood flow across the liver. Equation (1) therefore simplifies to: 
 
)Clf(Cl iuhep ×=
   (3) 
 
These drugs are therefore called “low extraction”, “low clearance” or “capacity-
limited”. They only have a low extraction during the first passage across the liver and 
have therefore a high bioavailability, if bioavailability is not limited by other processes 
than first pass hepatic metabolism. Since Cli decreases for most drugs in patients 
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with liver cirrhosis due to a decrease in the activity of cytochrome P450 isozymes 
(CYP) (61, 67) and/or glucuronyl transferases (73, 76, 145), the maintenance dose of 
such drugs has generally to be decreased in such patients. For drugs with a high 
binding to albumin (>90%), the situation may be more complex. The free fraction (fu) 
and the free concentration of such drugs can increase in patients with a low serum 
albumin concentration, e.g. patients liver cirrhosis or malnourished patients such as 
patients with cancer. An increase in the free concentration and/or fu of such drugs 
may be associated with increased toxicity, and, as shown in equation 3, also with an 
increased hepatic clearance (146, 147). The actual hepatic clearance of such drugs 
is therefore difficult to predict in patients with chronic liver disease.  
In between these two extremes, there are drugs with an “intermediate extraction”, 
showing characteristics of both groups. The dosage advice for such drugs in patients 
with liver cirrhosis is to start with a low dose and to up-titrate carefully in order to find 
the correct maintenance dose. 
Regarding dose adaptation in patients with cancer, it has to be recognized, however, 
that the dosing guidelines discussed above focus on patients with liver cirrhosis or 
fibrosis, but not on patients with increased transaminases and/or cholestasis which 
are found frequently among patients treated with antineoplastic drugs. Since the 
majority of antineoplastic drugs is metabolized by the liver (see Table 2) and is 
associated with severe dose-dependent toxicity, the question whether the dose has 
to be adapted in a patient with increased transaminases and/or cholestasis is 
important. The most prevalent liver disease in this group of patients is the presence 
of liver metastases, possibly resulting in cholestasis and/or portal hypertension (144, 
148, 149). Since many antineoplastic drugs are potentially hepatotoxic themselves 
(see Table 2), drug-induced liver disease may also be problematic in patients 
undergoing repetitive cycles of chemotherapy. 
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The aims of the current study were therefore 1) to categorize the antineoplastic drugs 
used according to pharmacokinetic criteria as discussed above 2) to compare this 
categorization with the dose recommendations in patients with liver disease given in 
the standard literature 3) to formulate dose recommendations for dose adaptation, 
and 4) to localize gaps in the current recommendations. 
 
Methods 
We screened Medline and Embase for studies dealing with dose adaptation and 
hepatic adverse effects for all antineoplastic drugs which were on the market in 
Switzerland by the end of the year 2004. The data bases were screened using the 
following MESH terms: antineoplastic agents, drug toxicity, pharmacokinetics, liver 
diseases. The references detected by the search in the databases were screened for 
other references dealing with the subjects. In addition to databases, the standard 
literature was screened for dose adaptation recommendations and adverse effects 
on the liver, including the “Swiss Compendium of Drugs” (150) (similar to the 
“Physicians’ Desk Reference” (55)), “Therapeutic drugs” of Dollery et al. (151) and 
“Hepatotoxicity” of H. J. Zimmerman (127). 
The antineoplastic drugs were categorized according to pharmacokinetic principles 
as outlined in the introduction and based on the reviews of Huet and Villeneuve (146) 
and Delco et al. (Delco 2005). The categorization system used is based on the 
hepatic extraction or bioavailability, and protein binding of the specific drugs (see 
Table 1). Values for bioavailability and protein binding could be found either in the 
original articles (cited in Table 3) or in other sources (55, 56, 150, 151). For hepatic 
extraction, data in the literature are rare, making it necessary to estimate extraction 
from bioavailability (see Table 1) or by the following equation: 
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Q
ClQ
E sys
×
=
0
   (4) 
 
where Q0 is the extrarenal dose fraction (the fraction of a drug which is not excreted 
unchanged by the kidney), Clsys the systemic clearance (determined in plasma) and 
Q the plasma flow across the liver. Most of the values for E in Table 3 are estimated 
using this equation. The values for Q0 and Clsys were obtained from the literature 
(54, 55, 150, 151), and Q was assumed to be 900 mL/min. 
Dosage recommendations originate either from the original articles or from the 
manufacturer as published in the PDR (55) and/or the Swiss Compendium of Drugs 
(150). 
Drug-induced liver disease was classified according to Benichou (152) and the 
severity of liver disease according to Donelli et al. (153) (see Table 2). 
 
Results 
Informations about all antineoplastic drugs on the market in Switzerland by the end of 
the year 2004 were collected. Using our search strategy, we identified a total of 112 
articles which were found to be relevant for our study. In 64 of them, kinetic data 
were reported and 48 contained hepatic adverse effects of antineoplastic agents. 
The 69 antineoplastic drugs on the Swiss market by the end of the year 2004 are 
listed in Table 3. From these 69 drugs, 15 fell into category 1, 9 into category 2 and 
25 into category 3. Twenty drugs could not be classified (category 4), demonstrating 
a lack of data about hepatic extraction and/or bioavailability. 
Fifty-two out of the 69 drugs have a Q0 value (extrarenal dose fraction, compare 
Table 3) >0.4, indicating that most antineoplastic drugs are heavily metabolized 
and/or excreted by the bile. Seven drugs have a Q0 value ≤0.4 and for 10 drugs, the 
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Q0 value could not be identified. For 25 drugs, metabolism by the cytochrome P450 
system (CYP) is important, and 18 drugs are excreted to a significant extent (> 5%) 
by the bile (vinca alkaloids, doxorubicin and derivatives, amsacrine, biculatamide, 
dactinomycin, estramustine, exemestan, irinotecan, imitanib, mitoxantrone, paclitaxel 
and topotecan). For 13 of these drugs, dose adaptation recommendations are given 
according to the serum bilirubin concentration and/or activity of alkaline phosphatase. 
For biculatamide, estramustine, exemestan and paclitaxel, there are general 
statements in the Swiss Compendium of Drugs and/or PDR that the dose should be 
adapted or stopped in patients with decreased liver function. For topotecan, there are 
no recommendations regarding dosage in patients with liver disease. For only 18 of 
the 69 drugs identified, recommendations for dose adaptation are based on 
published studies in patients with hepatic dysfunction. 
For 44 of the 69 drugs, significant adverse effects on the liver have been reported. 
This is important to realize, rendering drug-induced liver disease an important 
differential diagnosis in patients with malignant tumors and impaired hepatic function. 
 
Discussion 
Our study demonstrates that for antineoplastic drugs, there is a discrepancy between 
the general recommendations of how drugs should be dosed in patients with liver 
disease and the available kinetic data for these drugs. The most important gaps are a 
lack of information regarding hepatic extraction and of kinetic studies for critical drugs 
in patients with impaired liver function. 
As explained in the introduction, data about hepatic extraction are important for 
classification of a specific drug regarding hepatic elimination in patients with chronic 
liver disease, in particular liver cirrhosis. It is evident that such data are difficult to 
obtain, especially the determination of hepatic extraction of a drug, necessitating an 
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invasive procedure which is usually not performed before a drug is marketed. 
Bioavailability is only a surrogate for hepatic extraction, since a low bioavailability can 
originate from both a high hepatic extraction and/or a low intestinal absorption. For 
drugs with a low bioavailability (<40%), hepatic extraction should therefore be known, 
since, as explained above, this parameter is critical for rational drug dosing in 
patients with impaired liver function. In order to circumvent this invasive procedure in 
humans, a possibility would be to get such data using perfused livers from animals, 
e.g. pigs. To the best of our knowledge, no data have been published so far 
comparing hepatic extraction data for critical drugs between animals (such as pigs) 
and humans. Another possibility is to estimate hepatic extraction using Q0, systemic 
drug clearance and hepatic plasma flow (equation 4 and Table 3). As shown in Table 
3, the values obtained with this technique are in a satisfactory agreement with the 
bioavailability for most drugs, with some exceptions. 
Regarding antineoplastic agents, many of these drugs are used intravenously only, 
partially explaining the lack of data considering oral bioavailability. Nonetheless, 
taking into account the high prevalence of patients with impaired hepatic function 
among those treated with this type of drugs (154), such data should be available for 
all substances on the market. 
Kinetic studies have been conducted in particular in two conditions, namely in 
patients with cholestasis (as suggested by an increased serum bilirubin 
concentration) and in patients with hepatic metastases. Considering cholestasis, 
studies exist for most antineoplastic drugs with significant biliary elimination (see 
Table 3). These studies resulted in quantitative recommendations for dose 
adaptation, for example in jaundiced patients according to their serum bilirubin 
concentration. To the best of our knowledge, however, these recommendations have 
not been validated by kinetic and dynamic studies (including the incidence and 
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severity of dose-dependent adverse effects) in such patients. Considering 
cholestasis, it remains unclear, whether the serum bilirubin concentration is the best 
parameter for dose adaptation or whether the serum bile acid concentration and/or 
activity of alkaline phosphatase would be more suitable. 
Considering hepatic metastases, only few studies exist and they have generally not 
resulted in clear dose adaptation recommendations. Since hepatic metastases can 
be associated with portal hypertension and possibly porto-caval shunts (144, 148), 
the situation can be similar to patients with liver cirrhosis. Oral administration of drugs 
with a high hepatic extraction should therefore be performed cautiously and kinetic 
data for such drugs should be available in this type of patients when such drugs are 
approved. 
As shown in Table 3, treatment with antineoplastic agents can either lead itself to 
liver disease or, for drugs metabolized by the liver and/or excreted by the bile, to 
increased systemic toxicity in patients with liver disease. For such drugs, there is an 
additional type of toxicity which may be relevant. In several patients with chronic 
hepatitis B, the immunosuppressive effect of antineoplastic agents was associated 
with a flare up of their hepatitis due to increased replication of the hepatitis B virus 
(155-161). Since this condition is potentially fatal (161), but can be prevented by 
previous treatment or prophylaxis with antiviral agents, the immune status regarding 
hepatitis B should be known before treatment with antineoplastic drugs. 
In conclusion, there are currently considerable gaps in the data needed for safe 
administration of antineoplastic drugs in patients with decreased hepatic function. 
Drug authorities should urge pharmaceutical companies to provide such data before 
such drugs are approved. Considering kinetics, in particular data about oral 
bioavailability and/or hepatic extraction should be known. For drugs with a 
predominant hepatic metabolism and/or excretion, the kinetics in patients with liver 
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metastases and/or cholestasis should be known before marketing authorization is 
provided. 
 
References 
See below 
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Table 1 
 
Categorization of antineoplastic drugs screened according to pharmacokinetic 
variables. 
 
 
1. High hepatic extraction (category 1) 
• Hepatic extraction > 60% → oral bioavailability < 40% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not 
complete) 
 
2. Intermediate hepatic extraction (category 2) 
• Hepatic extraction 30 - 60% → oral bioavailability 40 - 70% in the case of 
complete intestinal absorption (or accordingly lower, if intestinal absorption is 
not complete) 
 
3. Low hepatic extraction (category 3) 
• Hepatic extraction < 30% → oral bioavailability > 70% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not 
complete) 
• In this category, protein binding may be relevant: for drugs with high binding to 
albumin (>90%), hepatic clearance may increase 
 
4. Hepatic extraction is not known (category 4) 
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Table 2 
 
Classification of liver disease and severity of liver dysfunction 
 
Parameter Pathophysiological condition 
and clinical significance 
Severity1 
Alanine 
aminotransferase 
(ALT) 
Breakdown (necrosis or 
apoptosis) of hepatocytes. 
Hepatocellular injury2 if > 2 x 
ULN3  
2-5 x ULN: moderate injury 
> 5 x ULN: severe injury 
Alkaline 
phosphatase 
Cholestasis4 if > 2 x ULN 
 
2-5 x ULN: moderate cholestasis 
> 5 x ULN: severe cholestasis 
Serum bilirubin 
concentration 
Cholestasis (exclude 
prehepatic causes)  
25 – 50 µmol/L: moderate 
> 50 µmol/L: severe 
Serum albumin 
concentration 
Impaired hepatic protein 
synthesis  
30 – 35 g/L: moderate 
< 30 g/L: severe 
Prothrombin 
activity 
Impaired hepatic protein 
synthesis  
40 – 70%: moderate 
< 40%: severe 
 
1The severity is classified according to Donelli et al. (153) with some modifications 
2Hepatocellular injury is defined according to Benichou (152) 
3ULN: upper limit of normal 
4Cholestasis is defined according to Benichou (152) 
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Table 3 
 
Kinetic data, hepatic adverse effects and dose recommendations in patients with liver disease of the antineoplastic drugs on the 
market in Switzerland by the end of the year 2001 
 
Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
Aldesleukin 4 Not known 0.18 
 
1     Frequent: 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia 
(150) 
Capillary leak syndrome, 
myelosuppression (162) 
Recommendations: Monitor patients 
for adverse effects, dose may need 
to be adjusted patients with liver 
disease (150, 151). Contraindicated 
in patients with elevated serum 
bilirubin (150). 
Alemtuzu-
mab 
4 Not known 0.15 
 
8      Infusion reaction (fever, chills, 
hypotension, nausea, 
vomiting), myelosuppression 
(162) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Aminoglu-
tethimide 
3 0.50 
N-acetylation, N-
hydroxylation 
(CYP) (151) 
1.0 
 
12 25 95 75 0.04 Sporadic: 
cholestasis, 
hyperbilirubinemia 
(127) 
Adrenocortical failure, 
dizziness (151) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Amsacrine 
 
4 1 
Glutathion 
conjugation, biliary 
excretion (150) 
1.40 5 97    Sporadic: 
cholestasis, 
hyperbilirubinemia 
(127) 
Myelosuppression, 
cardiotoxicity (arrhytmia), 
hypotonia, nausea and 
vomiting, alopecia, mucositis 
(163, 164) 
Recommendation: 50% dose 
reduction if serum bilirubin > 34 
µmol/l (82). Dose reduction (70% of 
normal dose) in patients with severe 
liver disease (150, 151). 
Anastrozole 
 
3 0.95 
N-dealkylation, 
hydroxylation 
(CYP), glucuroni-
dation (151) 
 50 45 80  0.2 Sporadic: 
cholestasis 
Nausea and vomiting, hot 
flashes, headache, musculo-
skeletal pain (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
Bicalutamide 
 
2 ≈1 
Oxidation (CYP), 
glucuronidation. 
Biliary elimination 
40% (150) 
 139 
 
98  500 0.56 
 
One case of 
fulminant liver failure 
(165) 
Blocked androgenic action (hot 
flushes, breast tenderness, 
gynecomastia, reduced libido 
and erectile function), diarrhea 
(162-164) 
Recommendations: Stop treatment if 
transaminases > 3 x ULN or in 
patients with hyperbilirubinemia 
(150) 
Bleomycin 
 
3 0.70 
Hydrolysis (151) 
0.30 3   90 0.07 Case reports: 
steatosis (127, 166) 
Pulmonary fibrosis, mucositis, 
hyperpigmentation, nausea 
and vomiting, hypotension 
(163, 164) 
Recommendations: No dose 
adjustment in patients with liver 
disease (151). Adjust dose 
according to dose-dependent 
adverse reactions 
Buserelin 
 
4 Not known 
 
 1.6  3    Blocked androgenic action (hot 
flushes, breast tenderness, 
gynecomastia, reduced libido 
and erectile function) (163, 
164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Busulfan 
 
2 1 
Oxidation, sulfation 
1.0 2.5 30 70 315 0.35 Sporadic: 
hepatocellular injury, 
cholestasis (167, 
168). 
Rare: venoocclusive 
disease (127). 
Myelosuppression, nausea 
and vomiting, seizures (162, 
164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Capecita-
bine 
1 0.97 
Carboxylesterase, 
Cytidine 
desaminase, 
phosphorylation 
 1.3 54 42 4000 ≈1 Frequent: 
hyperbilirubinemia 
Sporadic: 
cholestasis 
Rare: Hepatocellular 
injury (169) 
Myelosuppression, mucositis, 
nausea and vomiting, skin 
reactions (hand and foot 
syndrome) (162, 164) 
Studies: Increased bioavailability by 
20% in patients with moderate liver 
disease due to metastases (170). 
Recommendations: No dose 
adjustment in patients with moderate 
liver disease (170). Adjust dose 
according to dose-dependent 
adverse reactions 
Carboplatin 3 0.25 0.24 3 20  75 0.02 Rare: hepatocellular 
injury, cholestasis 
Myelosuppression, nausea 
and vomiting, nephrotoxicity, 
Recommendations: No dose 
adjustment in patients with liver 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(127) neurotoxicity, ototoxicity (163, 
164) 
disease (150). Adjust dose 
according to dose-dependent 
adverse reactions 
Cetuximab 4 Binding to EGFR 
in hepatocytes and 
skin (171) 
0.05 120   0.5  Frequent: mild 
elevation of 
transaminases and 
alkaline 
phosphatase (172) 
Infusion reaction 
(bronchospasm, urticaria, 
hypotension), acneiform skin 
reactions (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Chloram-
bucil 
3 1 
β-oxidation (151) 
1.0 1.5 99 87 175 0.19 Rare: hepatocellular 
injury (127) 
Case report: liver 
failure (173).  
Myelosuppression, nausea 
and vomiting, seizures, 
pulmonary fibrosis (162, 163)  
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Chlorme-
thine 
(Mechlor-
ethamine) 
4 1 
ethyleneimmonium 
ion (151) 
       Myelosuppression, nausea 
and vomiting, alopecia, 
ototoxicity (164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Cisplatin 3 0.65 
non-enzymatic 
degradation (174) 
0.3-1 0.5 90 - 5.0 0.01 Rare: hepatocellular 
injury (127) 
Myelosuppression, nausea 
and vomiting, visual 
disturbances, nephrotoxicity, 
neurotoxicity, ototoxicity (163, 
164) 
Recommendations: No dose 
adjustment in patients with liver 
disease (150, 151). Adjust dose 
according to dose-dependent 
adverse reactions 
Cladribine 2 Not known 0.4 6 25 55 1000   Myelosuppression, 
neurotoxicity, nephrotoxicity 
(162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Cyclophos-
phamide 
3 0.9 
Hydroxylation by 
CYP2B6, 2C19, 
2C9, 3A4 (175) 
0.80 7 15 75 75 0.08 Rare: Hepatocellular 
injury, cholestasis, 
hyperbilirubinemia 
(127). 
Case reports: 
venoocclusive 
Myelosuppression, nausea 
and vomiting, alopecia, 
hemorrhagic cystitis, 
pulmonary fibrosis, veno-
occlusive disease VOD (163, 
164) 
Studies: Decreased clearance of 
active drug and decreased 
production of active metabolites in 
patients with liver metastases (179), 
severe liver disease in the presence 
of Hodgkin’s disease (180) or liver 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
disease (176-178) cirrhosis (82).  
Recommendations: Monitor patients 
with liver disease for adverse 
effects. Dose reduction by 25% in 
patients with serum bilirubin > 50 
µmol/L (150) 
Cyproterone 3 1 
hydrolysis, 
hydroxylation, 
conjugation (151) 
19 38 95 88   Sporadic: 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia 
Rare: liver failure 
(181-185) 
decreased of libido and 
potency, gynecomastia, 
depression, diminished vitality, 
hepatotoxicity (163, 164) 
Recommendations: Monitor liver 
function. Stop treatment in patients 
with liver injury (150, 151) 
Cytarabine 1 0.90 
cytidine 
deaminase (151) 
3.0 2.3 13 <20 900 0.90 Sporadic to 
frequent: dose-
dependent 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia 
(127) 
Myelosuppression, 
arachnoiditis (nausea, fever, 
headache), nephrotoxicity, 
hepatotoxicity, mucositis, 
conjunctivitis, neurotoxicity, 
pulmonary toxicity (162, 164) 
Recommendations: 50% dose 
reduction if serum bilirubin > 34 
µmol/L, gradual increase while 
monitoring systemic toxicity (82) 
Dacarbazine 3 0.30 1.5 0.7 5  200 0.07 Case reports: 
venoocclusive 
disease (186, 187), 
hepatic vein 
thrombosis (187) 
Myelosuppression, nausea 
and vomiting, flu-like 
symptoms, flush, 
hepatotoxicity, renal 
impairment (162) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Dactino-
mycin 
4 0.70 
Biliary excretion 
50%-90% (151) 
12 36     Rare: hepatocellular 
injury, steatosis, 
venoocclusive 
disease (127) 
Myelosuppression, nausea 
and vomiting, diarrhea, 
mucositis, alopecia (162, 163) 
Recommendation: 50% dose 
reduction in patients with 
hyperbilirubinemia. Increase 
gradually while monitoring dose-
dependent toxicity (82). 
Dauno-
rubicin 
4 0.90 
Reduction, biliary 
excretion 40% 
(151) 
40 27     Rare: Venoocclusive 
disease when 
combined with 
radiation (127) 
Myelosuppression, nausea 
and vomiting, mucositis, 
alopecia, cardiotoxicity, 
diarrhea (162, 163) 
Recommendation: If serum bilirubin 
20 - 50 µmol/L 25% dose reduction, 
if serum bilirubin > 50 µmol/L 50% 
dose reduction (150, 151) 
Docetaxel 1 1 1.6 0.6 95  650 0.72  Myelosuppression, nausea Studies: Population kinetic studies 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
Oxidation by 
CYP3A4 (151). 
Biliary excretion 
75%, 10% as 
intact drug (150, 
151) 
(β) 
11 
(γ) 
and vomiting, diarrhea, 
sensory neuropathy, mucositis, 
alopecia, fluid retention 
syndrome (162, 163) 
show a 25% reduction of clearance 
in patients with transaminases > 1.5 
x ULN and alkaline phosphatase > 
2.5. In patients with moderate liver 
injury/cholestasis clearance was 
reduced by 27% (150, 151). 
Recommendation: If transaminases 
> 1.5 x ULN or alkaline phosphatase 
> 2.5 x ULN 25% dose reduction. If 
serum bilirubin is increased or 
transaminases > 3.5 x ULN or 
alkaline phosphatase > 6 x ULN 
docetaxel should not be 
adminstered (150, 151) 
Doxorubicin 1 0.95 
Reduction to 
doxorubicinol, 
sulfation, 
glucuronidation, 
biliary excretion 
50% (151, 153) 
17 26 80 5 1150 ≈1 Rare: in combination 
with etoposide, 
cyclophosphamide 
and cisplatin 
cholestasis and 
venoocclusive 
disease (127) 
Myelosuppression, nausea 
and vomiting, mucositis, 
alopecia, cardiotoxicity (162, 
163) 
Studies: In 5 patients with 
disseminated sarcoma, myelotoxicity 
and doxorubicin serum levels 
correlated with hyperbilirubinemia 
(188). In patients with hepatocellular 
carcinoma, myelotoxicity and serum 
doxorubicin/doxorubicinol levels 
correlated with hyperbilirubinemia 
(79, 189). In 17 patients with liver 
metastases and moderate liver 
disease, kinetics of doxorubicin were 
not changed but the half-life of 
doxorubicinol increased (190). In 4 
patients with moderate liver disease 
the half-life of doxorubicin was 
doubled (191). In patients with liver 
metastases and mild increase in 
transaminases or alkaline 
phosphatase, kinetics and toxicity of 
doxorubicin were not changed (79, 
189, 192, 193). 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
Recommendation: If serum bilirubin 
20 - 50 µmol/l: 50% dose reduction. 
If serum bilirubin > 50 µmol/l: 75% 
dose reduction (82, 150, 151, 194). 
Donelli et al. advise dose reduction 
only if serum bilirubin is > 50 µmol/L 
(153). 
Epirubicin 1 0.90 
Reduction 
Biliary excretion 
40% (195) 
20 39 85  1500 ≈1  
 
Myelosuppression, nausea 
and vomiting, mucositis, 
alopecia, cardiotoxicity (162, 
163) 
Studies: In patients with liver 
metastases and increased serum 
bilirubin, the half-life of 
epirubicin/epirubicinol was increased 
(196-198). In patients with 
hepatocellular carcinoma, epirubicin 
kinetics correlates with liver function 
and serum bilirubin (199). In patients 
with liver metastases, epirubicin 
kinetics correlates better with 
transaminases than with serum 
bilirubin (80, 200, 201). 
Recommendation: If serum bilirubin 
20 - 50 µmol/l: 50% dose reduction. 
If serum bilirubin > 50 µmol/l: 75% 
dose reduction (82, 150, 151) 
Estramustin
e 
2 0.90 
Oxidation, partial 
biliary excretion 
(202) 
0.04 1.3 99 44   Sporadic. 
Hepatocellular 
injury, cholestasis 
(150) 
Nausea and vomiting, 
diarrhea, edema, cardiac 
ischemia (164, 203)  
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Etoposide 3 0.65 
Esterases, 
glucuronidation. 
Biliary excretion 
<10%. 
0.30 8.1 95 50 48 0.04 Frequent. 
Hepatocellular injury 
(127).  
Case reports: 
Reactivation of 
hepatitis B virus 
Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, hypotension, 
hepatotoxicity (163, 164) 
Studies: In patients with mild to 
moderate liver disease, etoposide 
kinetics was not altered (81, 205, 
206). In patients with severe liver 
disease elimination and AUC were 
highly variable and tended to be 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(156), liver failure 
(204) 
increased in the case or impaired 
hepatic protein synthesis or 
hyperbilirubinemia (81, 205-207). 
Recommendations: Monitor patients 
with mild to moderate liver disease. 
If bilirubin 25 – 50 µmol/L or AST > 
180 U/L 50% dose reduction (82). 
Contraindicated in patients with 
decompensated liver disease (150, 
151). 
Exemestane 1 1 
CYP3A, biliary 
excretion 40% 
(208) 
19 24 90 42 10000 ≈1 Sporadic: 
hepatocellular injury, 
cholestasis (150) 
Hot flushes, increased 
sweating, nausea, fatigue, 
edema (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions. Be cautious in 
patients with cholestasis. 
Fludarabine 3 0.35 
 
2.4 10-
30 
 70 258 0.10  Myelosuppression, 
neurotoxicity (visual 
disturbances, seizures, coma, 
death), nausea and vomiting, 
mucositis, edema, 
hemorrhagic cystitis (162, 164) 
Recommendations: No dose 
adjustment recommended in 
patients with liver disease (150, 
151). 
Fluorouracil 1 0.95 
Dihydropyrimidine 
dihydrogenase 
0.3 0.25 94 28 11202 ≈1 Sporadic: 
hepatocellular injury 
when administered 
i.v. (127) 
Myelosuppression, nausea, 
vomiting, alopecia, palmar-
plantar erythrodysaesthesia, 
neurotoxicity (cerebellar) (163, 
164) 
Studies: In patients with liver 
metastases, a weak correlation with 
cholestasis was present (209), but 
no dose adjustment was 
recommended. 
Recommendations: Start with 50% 
of normal dose in patients with liver 
cirrhosis. Increase gradually while 
monitoring systemic toxicity (82, 
153). 
Flutamide 4 1 
Hydroxylation 
(210) 
 8 95    Sporadic: 
hepatocellular injury, 
hyperbilirubinemia 
Gynecomastia, nausea and 
vomiting, decreased libido, 
hepatotoxicity (163, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(150). 
Case reports: liver 
failure (211-218). 
according to dose-dependent 
adverse reactions 
Formestane 1 Not known  120 93 25    Hot flushes, alopecia, edema, 
nausea and vomiting, nausea 
and vomiting, constipation, 
arthralgia (151) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Fosfestrol 3 1  0.5  80     No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Gefitinib 2 CYP3A4, CYP2D6 
(164) 
20 27 90 50   Frequent: 
hepatocellular injury, 
cholestasis (55) 
Diarrhea, dry skin, nausea and 
vomiting, interstitial lung 
disease (162, 164) 
Recommendations: Reduce dosage 
by 50% or avoid in patients with liver 
disease (164) 
Gemcitabine 1 0.9 
Deamination, 
phosphorylation 
(150) 
25 1 – 
12 
(?) 
10  1500 ≈1 Frequent: hepa-
tocellular injury (self-
limiting) (150, 151) 
Myelosuppression, flue-like 
symptoms, nausea and 
vomiting, diarrhea, 
hepatotoxicity (162, 163)  
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Goserelin 3 0.4  4.0 25  135 0.06  Hot flushes, decreased libido, 
depression, edema (162, 164) 
Recommendations: Dose 
adjustment not recommended in 
patients with liver disease (150). 
Hydroxy-
carbamide 
3 0.4 0.5 5.0 80 80   Case report: 
fulminant liver failure 
(219) 
Myelosuppression, mucositis, 
skin reactions, alopecia, 
nausea and vomiting, 
nephrotoxicity, neurological 
disturbances (163, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Idarubicin 1 ≈1 
Oxidation, biliary 
excretion 8 – 17% 
(220, 221) 
 15.2 96 28 2000 ≈1 Frequent: 
hepatocellular injury, 
hyperbilirubinemia 
(150) 
Myelosuppression, mucositis, 
alopecia, nausea and vomiting, 
diarrhea, elevated liver 
enzymes, cardiotoxicity (162, 
222) 
Studies: In patients with metastases, 
kinetics of idarubicin is not changed 
(223, 224). 
Recommendation: If serum bilirubin 
20 - 34 µmol/l: 50% dose reduction. 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
If serum bilirubin > 34 µmol/l: 
contraindicated (150) 
Ifosfamide 3 0.5 
CYP3A (activation) 
(175) 
0.5 6.5  100 60 0.03 Sporadic: 
hepatocellular injury, 
hyperbilirubinemia 
(127) 
Myelosuppression, 
hemorrhagic cystitis, alopecia, 
nausea and vomiting (164, 
222) 
Recommendation: Monitor patients 
with preexisting liver disease closely 
(150). Contraindicated in patients 
with decompensated liver disease 
(151). 
Imatinib 3 0.95 
N-demethylation 
(CYP 3A), 20% 
biliary elimination 
(150) 
4.9 18 95 98   Sporadic: 
hyperbilirubinemia, 
hepatocellular injury 
(150). 
Myelosuppression, edema, 
myalgia, fatigue (164) 
 
 
Recommendations: Stop treatment if 
serum bilirubin > 3 x ULN or 
transaminases > 5 x ULN (150) 
Irinotecan 2 0.75 
Esterases, 
glucuronidation, 
CYP3A4. 
Biliary excretion 
25% (150, 225) 
75 10 65  430 0.36  Myelosuppression, cholinergic 
syndrome (diarrhea), alopecia, 
nausea and vomiting, 
mucositis, pulmonary toxicity 
(162, 164) 
Study: In patients with 
gastrointestinal cancer and 
cholestasis the AUC for SN-38 
(active metabolite) was 50% 
increased (serum bilirubin 1.1-1.5 x 
ULN) or 100% increased (>1.5 ULN) 
(226). 
Recommendation: If serum bilirubin 
> 1.5 x ULN/transaminases > 5 x 
ULN dose reduction according to 
dose-dependent toxicity. 
Contraindicated if serum bilirubin >5 
x ULN (150). According to (226) 350 
mg/2 in patients with serum bilirubin 
1.1-1.5 ULN and 200 mg/m2 when 
serum bilirubin >1.5 ULN. 
Letrozol 3 0.95 
CYP3A4, 2D6 
(150) 
1.9 45 60 100 40 0.04  Hot flushes, fatigue, nausea, 
vomiting, diarrhea, hypertonia, 
edema, depression (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Leuprorelin 3 Not known 0.5 3 46  140 0.05  Hot flushes, decreased libido, No dose adjustment 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
nausea, gynecomastia, edema 
(162, 164) 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Lomustine 3 1 
Cis- and trans-4-
hxdroxylation (227) 
1.70 10 - 100   Sporadic: 
hepatocellular injury 
(150) 
Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, elevated liver 
enzymes, neurological 
disturbances, pulmonary 
fibrosis (164, 203) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Medroxy-
progesteron 
1 1 
CYP3A4 
0.6 36 94 <10 1270 ≈1 Rare: cholestasis, 
peliosis hepatic 
(150) 
Weight gain, edema, 
Cushing’s syndrome, 
pulmonary and cerebral 
thromboembolism (164, 222) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Megestrol 4 1 
Glucuronidation 
(151) 
 18     Rare: hepatocellular 
injury, 
hyperbilirubinemia 
(150) 
Weight gain, edema, 
Cushing’s syndrome, 
pulmonary and cerebral 
thromboembolism (164, 222) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Melphalan 2 0.9 
Hydroxylation 
(151) 
0.6 1.5 80 70 515 0.52 Case reports: veno-
occlusive disease 
(VOD) (150) 
Myelosuppression, nausea 
and vomiting, diarrhea, 
mucositis, alopecia, 
amenorrhea, pulmonary 
fibrosis, hepatotoxicity (VOD) 
(164, 222) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Mercapto-
purine 
1 0.9 
Xanthine oxidase 
(thiouric acid), 
thiopurine 
methyltransferase 
(151) 
0.6 0.9 19 12 765 0.77 Frequent: 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia in 
6 – 40% (127). 
Case reports: liver 
failure (228-231), 
venoocclusive 
disease (127). 
Myelosuppression, nausea 
and vomiting, diarrhea, 
hyperuricemia and/or 
hyperuricosuria, hepatocellular 
injury, mucositis, pancreatitis, 
nephrotoxicity, interstitial 
pneumonitis, alopecia, 
oligospermia (162, 222) 
Recommendations: Monitor liver 
function. Contraindicated in patients 
with decompensated liver disease 
(150) 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
Risk may be higher 
in patients with 
reduced activity of 
thiopurine 
methyltransferase 
Methotre-
xate 
3 0.05 0.70 7.2 50 70 145 0.01 Sporadic: Fatty liver, 
fibrosis, cirrhosis 
during long-term 
treatment with 
immunosuppressive 
doses (128, 232-
237). 
Case reports: 
hepatocellular injury, 
acute liver failure 
when used as an 
antineoplastic agent 
(156, 238-241) 
 
Myelosuppression, mucositis, 
nausea and vomiting, diarrhea, 
hepatotoxicity, nephrotoxicity, 
neurological disturbances 
(164, 222) 
Studies: No correlation between liver 
function and methotrexate serum 
levels (242). 
Recommendation: Close monitoring 
in patients with decompensated liver 
disease. Reduce dose in the 
presence of ascites and/or 
decreased renal function (150, 151) 
Mitomycine 
 
4 0.9 0.3 0.5     Rare: steatosis  
Case reports: 
venoocclusive 
disease (127) 
Myelosuppression, nausea 
and vomiting, nephrotoxicity,  
hemolytic uremic syndrome, 
hepatotoxicity (VOD) (164, 
222) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Mitoxantrone 1 0.95 
mono- or 
dicarboxylation 
(inactive), biliary 
excretion 25% 
(150) 
10 - 
15 
57 76 - 750 0.79 Frequent: 
hepatocellular injury 
(127) 
Myelosuppression, mucositis, 
nausea and vomiting, diarrhea, 
menstrual disorders, 
neurological disorders, 
cardiotoxicity, alopecia, 
hepatotoxicity, nephrotoxicity 
(162, 164, 222) 
Studies: Clearance reduced by 50% 
in patients with moderate liver 
disease (243). 
Patients with serum bilirubin < 60 
µmol/L tolerate 14 mg/m2, patients 
with serum bilirubin > 60 µmol/L and 
bad performance status have higher 
mortality with this dosage (244). In 
patients with liver metastases, half-
life of mitoxantrone correlated with 
serum bilirubin and cholestasis 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(245). 
Recommendation: Dose adjustment 
(8 mg/m2) or contraindicated (bad 
performance status) in patients with 
serum bilirubin > 60 µmol/L (244) 
Nimustine 4 1  0.6 34      No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to adverse reactions 
Oxaliplatin 4 ≈0.5, 
Reduction (non-
enzymatic), biliary 
excretion 5% (246) 
 260 75     Myelosuppression, nausea 
and vomiting, mucositis, renal 
failure, neurotoxicity, visual 
disturbances, 
thromboembolism (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Paclitaxel 2 0.95 
CYP 3A, 2C8. 
Biliary excretion 
>5% (247) 
2.0 3 95  380 0.41 Sporadic: 
hepatocellular injury, 
cholestasis 
Rare: 
hyperbilirubinemia, 
liver failure (150) 
Myelosuppression, peripheral 
neuropathy, arthralgia, 
myalgia, hypotension, nausea 
and vomiting, diarrhea, 
mucositis, cardiotoxicity 
(arrhythmias, bradycardia) 
(164, 222) 
Studies: Liver disease/liver cirrhosis 
appears to be a risk factor liver for 
systemic toxicity (248, 249). 
Increased risk for myelosuppression 
in patients with increased 
transaminases and/or serum 
bilirubin > 25 µmol/L (250). In 
patients with increased 
transaminases (3-10 x ULN) and 
hyperbilirubinemia (1.3 – 2 x ULN) 
clearance was decreased by ≈ 40% 
(251) 
Recommendation: Monitor patients 
with liver disease well for adverse 
effects. Do not administer in patients 
with decompensated liver disease 
(150, 251) 
Raltitrexed 4 0.5 
Polyglutamate 
derivative (252) 
7.0 2 93    Frequent: 
hepatocellular injury 
Sporadic: 
Myelosuppression, nausea 
and vomiting, diarrhea, 
mucositis, rash, conjunctivitis, 
Recommendations. No dose 
adjustment in patients with mild to 
moderate liver disease. 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
cholestasis, 
hyperbilirubinemia 
Case report: liver 
failure (253) 
alopecia, arthralgia, 
hepatotoxicity, 
hyperbilirubinemia, edema, 
flue-like symptoms, (164) 
Contraindicated in patients with 
decompensated liver disease (150). 
Rituximab 4 Not known  68      Infusion related reactions, B-
cell depletion, 
myelosuppression, mucositis, 
tumor lysis syndrome (162, 
164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Tamoxifen 4 1 
Hydroxylation, N-
dealkylation (CYP 
2C9, 2D6, 3A4, 
2C8) (151) 
60 4 – 
11 
days 
99    Sporadic: 
hepatocellular injury, 
cholestasis, fatty 
liver (127) 
Rare: liver failure 
(254-256) 
Hot flushes, nausea, edema, 
vaginal bleeding, glaucoma, 
thromboembolism, 
hepatotoxicity, hypercalcemia 
(164, 222) 
Studies: In a patient with liver 
metastases liver function 
deteriorated one year after start of 
tamoxifen (257). In a randomized 
trial in patients with hepatocellular 
carcinoma, liver function was not 
affected (258). 
Recommendation: Monitor liver 
function and systemic toxicity in 
patients with preexisting liver 
disease. 
Temozolo-
mide 
3 0.9 
non-enzymatic 
 1.8 15 100    Myelosuppression, nausea 
and vomiting, fatigue, 
headache, diarrhea (162, 164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Thiotepa 3 0.5 
CYP 2B1, 2C11 
(259) 
 2.4 99  315 0.18 Case report: liver 
failure (260) 
Myelosuppression, gonadal 
dysfunction, nausea and 
vomiting, neurotoxicity, 
mucositis (203, 261) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Tioguanine 4 >0.9, 
Thiopurine 
methyltransferase 
(?) 
 5 - 9     Rare: hepatocellular 
injury, cholestasis 
(127). 
Case reports: Veno-
occlusive disease 
Myelosuppression, tumor lysis 
syndrome, nausea and 
vomiting, mucositis, 
hepatotoxicity (162, 164) 
Recommendation: Monitor liver 
function after administration of high 
doses. Contraindicated in patients 
with decompensated liver disease 
(150). 
Antineoplastic Drugs 
 82 
Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(262, 263) 
Topotecan 2 0.6 
Esterases.  
Biliary excretion 
20% (264) 
1.9 2.4 35 32 825 0.55  Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, diarrhea (162, 164) 
Studies: 14 patients with increased 
transaminases and/or 
hyperbilirubinemia (some with 
cirrhosis) were treated with 1.5 
mg/m2. Topotecan clearance 
correlated with ICG clearance but no 
more adverse effects were observed 
in patients with liver disease (265). 
On the other hand, two thirds of 
patients with hepatocellular 
carcinoma treated with topotecan 
developed grade IV neutropenia 
(266). 
Recommendation: No dose 
adjustment for patients with hepatic 
dysfunction but monitor patients well 
for systemic toxicity (265). 
Toremifen 3 1 
CYP3A4 (N-
dealkylation, 
hydroxylation) 
Enterohepatic 
circulation (267) 
12-15 148 99 100 75 0.08 Sporadic: 
hepatocellular injury, 
cholestasis, fatty 
liver (127) 
Hot flushes, edema, vaginal 
bleeding, hepatotoxicity, 
thromboembolism, 
hypercalcemia (162, 164) 
Studies: In 10 patients with liver 
cirrhosis or fibrosis the elimination 
half-life was increased by 75% and 
clearance decreased by 28% (267). 
Recommendation: Dose reduction in 
patients with liver cirrhosis by 50%, 
gradual increase while monitoring 
adverse effects (150). 
Trastuzu- 
mab 
4 Not known 0.04 140      Infusion related reactions, 
cardiotoxicity, hepatotoxicity, 
pulmonary infiltrates, 
exacerbation of chemotherapy-
induced neutropenia (162, 
164) 
No dose adjustment 
recommendations available. 
Recommendations: Adjust dose 
according to dose-dependent 
adverse reactions 
Tretinoin 
 
4 CYP2C8, 
Isotretinoin, 4-oxo-
retinoic acid (55) 
 1.25 95    Frequent: 
hepatocellular injury 
(164) 
Capillary leak syndrome 
(weight gain, pulmonary 
infiltrates, pleural and/or 
Recommendation: Need for dosage 
adjustments in patients with hepatic 
impairment has not been shown. A 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
pericardial effusions), 
leukocytosis, neurological 
disturbances, dyslipidemia, 
hepatotoxicity, hypercalcemia 
(162, 164) 
dose reduction to 25 mg/m2 is 
recommended as a precautionary 
measure (55). 
Triptorelin 3 
 
0.52 0.5 3   85 0.05  Hot flushes, decreased libido, 
impotence, gynecomastia 
(162) 
Studies: As compared to 6 healthy 
young males, 6 patients with normal 
renal function and hepatic 
impairment (Child A or B) had 
decreased total clearance (57 
versus 210 mL/min) and prolonged 
elimination half-life (7.6 versus 2.8 
hours) after a single intravenous 
bolus of 0.5 mg. Despite these 
differences after intravenous dosing, 
dose reduction of the sustained-
release formulation used clinically is 
judged not necessary, because its 
release rate is much slower than its 
elimination rate (268). 
Recommendation: Dosage reduction 
of sustained-release triptorelin does 
not appear to be necessary in 
patients with liver disease (268). 
Vinblastine 1 1 
CYP3A4, 
biliary excretion 
>50% (151) 
20 25 75  865 0.96  Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, neurotoxicity 
(peripheral and autonomic), 
inappropriate ADH secretion 
(SIADH) (164, 222) 
Recommendation: If serum bilirubin 
> 50 µmol/L → 50% dose reduction 
(150). 
Vincristine 3 0.9 
CYP3A4, 
biliary excretion 
70% (151) 
8.0 23 75  140 0.14  Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, neurotoxicity 
(peripheral and autonomic), 
inappropriate ADH secretion 
Studies: In the presence of 
cholestasis/hyperbilirubinemia β-
half-life was prolonged (77). In 
patients with leukemia or lymphoma 
and cholestasis, AUC and toxicity 
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Drug Cat1 Kinetic parameters Hepatic adverse 
effects9 
Dose-dependent adverse 
reactions 
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3 
(L/kg) 
t½4 
(h) 
PB5 
(%) 
F6 
(%) 
Clsys7 
(mL/min) 
E8    
(SIADH) (164, 222) were increased (269). 
Recommendation: If serum bilirubin 
> 50 µmol/L → 50% dose reduction 
(150). Some authors advise 50% 
dose reduction also if alkaline 
phosphatase is increased (82). 
Vindesine 4 Not known 
CYP 3A, biliary 
excretion 
8.8 24   17.5   Myelosuppression, nausea 
and vomiting, alopecia, 
mucositis, neurotoxicity 
(peripheral and autonomic), 
inappropriate ADH secretion 
(SIADH) (164, 222) 
Recommendation: Monitor patients 
for dose-dependent adverse effects. 
Dose may need to be adjusted in 
patients with hyperbilirubinemia (see 
vincristine) (150). 
Vinorelbine 1 0.85 
CYP 3A, biliary 
excretion 50% (78, 
151) 
75 30 15 ≈40    Myelosuppression, 
neurotoxicity (peripheral and 
autonomic), mucositis, 
alopecia, pulmonary toxicity 
(162, 164) 
Studies: In 19 patients with liver 
metastases, clearance was reduced 
by 50% in patients with >75% of the 
liver replaced by tumor (270). 
Recommendation: 50% dose 
reduction if more than 75% of liver 
replaced by tumor (270) or if serum 
bilirubin > 34 µmol/L (78). 
 
1Cat = drug category. Drugs were categorized as follows: Category 1: high hepatic extraction (E) (E > 60%, bioavailability < 40%), category 2: intermediate 
hepatic extraction (E = 30-60%, bioavailability 40-70%), category 3: low hepatic extraction (E < 30%, bioavailability >70%), category 4: hepatic extraction not 
known 
2Q0: extrarenal dose fraction = fraction metabolized or excreted by bile (1 - Q0: fraction excreted unchanged by the kidney) 
3Vd = volume of distribution in L per kg. For calculation, body weight was assumed to be 70 kg. 
4 t½: dominant half-life 
5PB: Fraction bound to proteins (protein binding in %) 
6F: Bioavailability 
7Clsys: systemic clearance (L/min) 
8E: hepatic extraction, calculated as described in equation 4 
9Frequency of hepatic adverse effects: frequent > 10% of patients treated, sporadic: 1-10%, rare: < 1% 
Abbreviations: CYP = cytochrome P450, ULN = upper limit of normal 
Characterization of liver disease and severity of liver dysfunction: compare Table 2 
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6.2 Dose Adaptation of Psychotropic Drugs in Patients with 
Liver Disease 
 
 
This paper has been submittet to Drug Safety in April 2008 (see below).  
 
A complete list of the investigated psychotropic drugs can be found in the electronic 
appendix on CD-ROM.
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Abstract 
Dose adjustment of psychotropic drugs in patients with liver cirrhosis may be 
important as most of these drugs are predominantly eliminated by the liver and many 
of them have dose-dependent adverse reactions. Since no surrogate parameter is 
available to predict hepatic metabolism of drugs, dose adjustment according to 
pharmacokinetic properties of the drugs is proposed. Psychotropic drugs 
(antiepileptics, anti-parkinson drugs, psycholeptics such as antipsychotics, 
anxiolytics, sedatives and hypnotics, and psychoanaleptics such as antidepressants, 
psychostimulants and anti-dementia drugs) marketed in Switzerland in 2006 were 
therefore classified according to their hepatic extraction and/or bioavailability to 
predict their kinetic behaviour in cirrhotic patients. The expected changes in hepatic 
metabolism predicted by pharmacokinetic properties were compared with the results 
from kinetic studies carried out in patients with liver disease. These studies were 
identified using MEDLINE searches. 
Of the 116 psychotropic drugs available on the Swiss market by the year 2006, only 
12 were predominantly eliminated through the kidney. For 5 substances no Q0-value 
could be determined because of lack of pharmacokinetic data. Of 106 drugs that 
could be classified according to their bioavailability and/or hepatic extraction, 27% 
were categorised as high, 25% as intermediate and 48% as low extraction drugs. 
Pharmacokinetic studies in patients with liver disease were available for 55 of 99 
drugs eliminated predominantely by the liver (Q0 ≥ 0.5). Only few kinetic studies in 
patients with liver disease were found for antipsychotics, anti-parkinson drugs and 
antidepressants, except for selective serotonin reuptake inhibitors and some newer 
antidepressants. The expected changes in pharmacokinetics were generally in good 
agreement with the changes reported in pharmacokinetic studies. For 12 drugs, the 
observed changes in pharmacokinetics from clinical studies were different from the 
changes expected based on their classification. However, for low extraction drugs 
metabolised by cytochrome P450 isozymes clearance may be reduced up to 50%. 
In conclusion, the classification of drugs according to their hepatic extraction and/or 
bioavailability is a useful tool for dose adjustment, if information from clinical studies 
is lacking. There is a gap of information about pharmacokinetic changes in patients 
with liver cirrhosis for a large part of centrally acting drugs. Kinetic studies for 
centrally acting drugs with predominant hepatic metabolism should be carried out in 
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patients with liver disease to allow precise dose recommendations for enhancing 
patient safety. 
 
Introduction 
The liver is involved in the clearance of many drugs through a variety of metabolic 
pathways and/or biliary excretion of unchanged drugs or metabolites. Alterations of 
these metabolic and/or excretory functions in patients with liver disease, most 
pronounced in patients with liver cirrhosis, can lead to drug accumulation or, less 
often, to failure to form an active metabolite.  
The factors affecting drug disposition in patients with chronic liver disease have been 
discussed in numerous reviews.(1, 2, 7, 25, 271-274) In these reviews, drugs are 
classified according to their hepatic extraction (Eh), which determines mainly the 
hepatic clearance of drugs. Since, until now, no in vivo surrogate parameter exists to 
predict hepatic clearance of drugs, predictions concerning dose adjustment in 
patients with liver disease can only be made based on the pharmacokinetic 
properties of the drugs administered.(25) Dose recommendations made in this paper 
are based on the classification of the drugs according to their Eh. Only the basic 
principles underlying this classification will be reviewed in this article. For further 
information, refer to the publication of Delco et al.(25) or Tchambaz et al..(60)  
Hepatic clearance (Clhep) is defined as the volume of blood from which a drug is 
removed completely by the liver per unit time. Hepatic clearance can be expressed 
as (equation 1): 
    
( )
Q)Clf(
QClfCl
iu
iu
hep
+×
××
=
   (Eq. 1) 
 
where Q is the blood flow across the liver, fu is the unbound fraction (free) and Cli is 
the intrinsic clearance of the drug. 
When (fu x Cli) >> Q, equation 1 can be simplified to Clhep ≈  Q. In this case, the 
blood flow across the liver becomes rate-limiting for hepatic clearance of a drug. Due 
to their high hepatic extraction, this class of drugs has a low bioavailability and is 
insensitive to changes in protein binding or activity of drug metabolising enzymes. 
Bioavailability of high extraction drugs may increase significantly in patients with liver 
cirrhosis due to porto-systemic shunts resulting from portal hypertension.(275) Also 
Psychotropic Drugs 
 89
altered hepatic blood flow will lead to changes in hepatic clearance of high extraction 
drugs.(272) Therefore, initial dose of orally administered high extraction drugs has to 
be reduced according to the expected increase in bioavailability and the maintenance 
dose according to bioavailability and impaired hepatic blood flow across the liver. For 
intravenous administration, the maintenance dose has to be reduced, since only the 
reduction in hepatic blood flow has to be considered. 
In contrast, hepatic clearance of drugs for which (fu x Cli) << Q is mainly determined 
by the capacity of the liver to metabolise these substances. For such drugs, equation 
1 can be simplified to Clhep ≈ (fu x Cli). Liver cirrhosis can alter Cli of these drugs by 
affecting the activity of cytochrome (CYP) P450 isozymes and/or glucuronyl 
transferases, whereby oxidation seems to be more sensitive than glucuronidation.(1, 
273) Because of a low hepatic extraction during the first passage across the liver, 
such drugs have a high bioavailability, if bioavailability is not limited by processes 
different from first pass hepatic metabolism. Treatment can be started with normal 
initial doses, because no significant alteration in bioavailability is expected. 
Maintenance doses may be reduced due to impaired hepatic clearance, especially for 
drugs mainly metabolised by CYP 450 isozymes. Hepatic clearance of low extraction 
drugs highly bound to albumin may additionally be influenced by changes in plasma 
protein binding. In patients with liver cirrhosis protein binding may be diminished due 
to lower serum albumin resulting from impaired albumin synthesis (276) and/or due to 
accumulation of endogenous compounds (e.g. bilirubin), competing for plasma 
protein binding sites. As a consequence, the free (unbound) fraction of a drug may 
be increased and dose adjustment should be made according to the free plasma 
concentration of the drug (e.g. phenytoin, valproate) or according to 
pharmacodynamic parameters (e.g. phenprocoumon). 
Drugs with an intermediate hepatic extraction show characteristics of both groups. 
The hepatic clearance of such drugs can be influenced by all the parameters 
included in equation 1. Initial doses should therefore be reduced according to the 
expected increase in bioavailability and maintenance dose should be further adjusted 
according to the expected decrease in intrinsic hepatic clearance. 
Drugs acting on the central nervous system (e.g. anxiolytics, sedatives, 
antidepressants, antipsychotics, antiepileptics) are often prescribed to patients with 
liver cirrhosis due to a variety of psychiatric symptoms or illnesses associated with 
liver cirrhosis.(277) Benzodiazepines may be used for the management of alcohol 
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deprivation, for insomnia or as a pre-medication before upper gastrointestinal 
endoscopy. A study evaluating drug use in patients with liver cirrhosis showed that, 
beside the benzodiazepines, also antipsychotics, antidepressants and/or 
antiepileptics were frequently prescribed.(278) In fact, chronic depressive symptoms 
are not uncommon in cirrhotic patients.(279) 
Most of the psychotropic drugs are lipophilic and are extensively metabolised through 
the liver, involving also biotransformation by CYP450 isozymes.(277) In cirrhotic 
patients, the decreases in hepatic clearance and hepatic extraction result in an 
increased risk for dose-related adverse drug reactions of psychotropic drugs. But not 
only pharmacokinetic changes should be considered when prescribing centrally 
acting drugs, also pharmacodynamic changes have been reported in patients with 
liver cirrhosis.(272) 
Prescribing to patients with liver cirrhosis requires careful drug selection and dose 
adjustment based on the pharmacokinetic profile to prevent adverse effects. 
Classification according to pharmacokinetic properties and results from clinical trials 
in patients with liver cirrhosis and/or other liver diseases can therefore help to select 
and administer drugs more rationally in this group of patients. The aims of this work 
were therefore: (i) to collect pharmacokinetic data of psychotropic drugs 
(antiepileptics, anti-parkinson drugs, antipsychotics, anxiolytics, sedatives, hypnotics, 
antidepressants, psychostimulants and anti-dementia drugs) and to classify the drugs 
based on their pharmacokinetic profile; (ii) to compare the dose recommendations 
based on this classification with recommendations from the product information and 
from published clinical studies; (iii) to formulate recommendations for dose 
adjustment in patients with liver cirrhosis; and (iv) to localise gaps in the current 
databases and recommendations. 
 
Methods 
We searched the database MEDLINE for studies dealing with pharmacokinetics, 
hepatic adverse effects and/or dose adjustment in patients with liver disease for all 
psychotropic drugs registered in Switzerland in 2006. To perform our literature 
search, the following medical subject heading (MeSH) terms were used: 
‘pharmacokinetics’, ‘metabolism’, ‘cytochromes’, ‘drug toxicity’, ‘liver diseases’, 
‘central nervous system agents’, and the specific generic name of each psychotropic 
drug. The references of the publications found were screened for additional relevant 
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studies. In addition to databases, the standard literature such as the Swiss 
Compendium of Drugs(280) containing product information of the drugs registered in 
Switzerland, the Physicians’ Desk Reference,(281) as well as Therapeutic 
Drugs,(282) DRUGDEX® System from Thomson Healthcare(283), Avery’s Drug 
Treatment(284), Goodman & Gilman’s: The pharmacological basis of 
therapeutics(285)  and Hepatotoxicity(286) were used to find data about 
pharmacokinetics, hepatic adverse effects, dose-dependent adverse effects, and 
dose recommendations of the psychotropic drugs investigated. 
The psychotropic drugs were categorised as outlined in the previous section and 
according to a previous review of antineoplastic agents by Tchambaz et al..(60) The 
classification is based on the hepatic extraction and/or bioavailability of a given drug 
(table I). Because data for hepatic extraction is rare in the literature, hepatic 
extraction was estimated using the following equation (equation 2):  
 
     
Q
ClQ
Q
Cl
E sys0hep
×
==
    (Eq. 2) 
 
where Q0 is the dose fraction metabolised or excreted extra-renally (1-Q0 is the dose 
fraction excreted non-metabolised by the kidney), Clsys is the systemic clearance 
(determined in plasma) and Q the plasma flow across the liver. Q was assumed to be 
900 mL/min(60) and the values for Q0 and Clsys were obtained from the literature. If 
bioavailability and calculated hepatic extraction were not consistent, drugs were 
classified according to the measured value for absolute bioavailability except when 
bioavailability was lower than expected from hepatic extraction due to incomplete 
intestinal absorption. 
Dose recommendations are based on the original articles from clinical studies, on the 
product information published in the Swiss Compendium of Drugs(280) or the 
Physicians’ Desk Reference,(281) and based on the classification of the drugs 
according to their hepatic extraction. The available strengths and oral dosage forms 
of the drugs marketed in Switzerland were also taken into account for the dosage 
recommendations made. 
Drug-induced liver disease was classified according to Benichou(287) if enough data 
was available for classification (see Table II). In addition to the hepatic adverse 
effects also the most important dose-dependent adverse effects of the psychotropic 
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drugs were retrieved from the standard literature and listed in Table IV.(280-283) 
Occurrence of such symptoms may serve as an indicator for drug accumulation in the 
case of insufficient dose adaptation to impaired liver function. 
 
Results 
A total of 116 psychotropic drugs were available on the Swiss market by the year 
2006. The complete list of these drugs (antiepileptics (n=18), anti-parkinson drugs 
(n=13), antipsychotics (n=22), anxiolytics, sedatives and hypnotics (n=29), 
antidepressants (n=24), psychostimulants (n=6) and anti-dementia drugs (n=4)) 
together with their pharmacokinetic properties and dose recommendations is 
available at http://kpharm.unibas.ch. 
Data about pharmacokinetic properties of the drugs were either extracted from the 
standard literature(280-285, 288) or were based on published pharmacokinetic 
studies or reviews.(289-329) Only 12 of 116 psychotropic drugs (10%) are 
predominantly eliminated through the kidney (Q0-value <0.5): amantadine, lithium, 
phentermine, phenylpropanolamine, pramipexole, sulpiride, tiapride, and the newer 
antiepileptics gabapentin, levetiracetam, pregabalin, topiramate, and vigabatrin. For 5 
substances, no Q0-value could be determined because of lack of pharmacokinetic 
data. The remaining drugs are predominantly eliminated by the liver either through 
CYP-dependent metabolism and/or through conjugation. CYP isozymes involved in 
the phase I metabolism of antipsychotics are mainly CYP 2D6, 3A4 and to a lesser 
extent 1A2. CYP 2D6 plays a major role in the metabolism of tricyclic antidepressants 
and selective serotonin reuptake inhibitors (SSRIs). Whereas most of the 
benzodiazepines are metabolised through CYP 2C19 and/or 3A4, the major 
metabolic pathway of oxazepam, lorazepam and temazepam is glucuronidation. 
Based on their bioavailability and/or hepatic extraction, 29 substances were classified 
as high extraction drugs, 26 as drugs with intermediate hepatic extraction, and 51 as 
low extraction drugs (Table III). Only 10 substances (8.6%) could not be classified 
because of lack of pharmacokinetic data. Most of the antiepileptic drugs were 
classified as low extraction drugs, except oxcarbazepine, the only high extraction 
drug in this therapeutic drug class. Also benzodiazepines were commonly classified 
as low extraction drugs, except flurazepam, midazolam and triazolam. In contrast, 8 
of 13 anti-parkinson drugs available, namely biperiden, bromocriptine, cabergoline, 
dihydroergocryptine, entacapone, levodopa, pergolide, and selegiline were classified 
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as high extraction drugs. However, the maintenance dose of anti-parkinson drugs is 
commonly found by slow up-titration. Since treatments are therefore usually started 
at low doses, initial doses have not to be reduced additionally in patients with liver 
cirrhosis. 
The expected dose-dependent adverse reactions in case of accumulation of a drug in 
patients with liver cirrhosis can usually be deduced from its pharmacological effect 
and receptor affinity.(280-283, 288, 289, 327, 330, 331) Since such adverse effects 
are important for guiding drug therapies, the most common dose-dependent adverse 
effects of selected therapeutic drug classes are summarised in Table IV.  
Hepatic adverse drug effects have been reported for 88 of the 116 drugs studied 
(76%).(280-283, 286, 332-363) Phenothiazines may cause cholestatic liver injury, 
while some older antiepileptic drugs are associated with induction of acute 
intermittent porphyria in predisposed patients. The use of benzodiazepines may 
induce hepatic encephalopathy in cirrhotic patients. For other drug classes, no 
specific pattern of hepatic adverse reactions has been reported. Tricyclic 
antidepressants, for example, have been associated with hepatocellular as well as 
cholestatic liver injuries. 
Pharmacokinetic studies, either published in Medline(9, 44, 295, 307, 311, 344, 351, 
364-423) and/or in the respective product information(280, 281) or standard 
literature,(282, 283) evaluating the kinetic properties of drugs in patients with liver 
disease could be found for 56% of the drugs with known predominant hepatic 
elimination (55 of 99). Of the individual therapeutic groups assessed, for 3 of 4 anti-
dementia drugs (75%) pharmacokinetic data in patients with liver cirrhosis was 
available. The only exception was memantine, for which 50% of the dose is 
eliminated unchanged through the kidney. Also for a high proportion of the 
anxiolytics, hypnotics and sedatives (20 of 28 drugs; 71%) as well as for 
antiepileptics (9 of 19 drugs; 64%), pharmacokinetic information in patients with liver 
disease was available. The drug class, for which only sparse information about 
pharmacokinetic changes in patients with liver disease was available, are the 
antipsychotics. For only 5 of 17 drugs (29%), clinical studies in patients with liver 
disease could be found (for aripiprazole, promazine, quetiapine, risperidone and 
sertindole). The best studied drug class are the selective serotonin reuptake 
inhibitors (SSRIs). For all of the 6 substances available in Switzerland (citalopram, 
escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) data about 
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pharmacokinetics in patients with liver cirrhosis could be found. In Table V, 
pharmacokinetic data and dosage recommendations are provided for drugs with a 
high hepatic extraction. For the drugs with intermediate or low hepatic extraction, the 
data are available on http://kpharm.unibas.ch.  
 
Discussion 
Since no reliable surrogate parameter for hepatic drug metabolism is available, dose 
adjustment based on the hepatic extraction of drugs has been proposed in patients 
with liver diseases, provided that pharmacokinetic properties of a drug have been 
studied.(25) Of 116 psychotropic drugs studied, only 10 substances could not be 
classified according to their hepatic extraction. These drugs can be replaced in 
patients with liver cirrhosis by adequate alternatives without any problems. Because 
of the high proportion of centrally acting drugs eliminated predominantly through the 
liver, dosage has to be reduced for most of them in patients with liver cirrhosis in 
order to prevent dose-dependent adverse effects. When comparing the results from 
clinical pharmacokinetic studies in patients with liver cirrhosis and other liver 
diseases (available for 55 drugs) with the estimates based on measured or calculated 
hepatic extraction, only for 12 drugs the recommendations were not fully congruent. It 
must be pointed out, that for low extraction drugs, the observed reduction in drug 
clearance in patients with liver disease may be as high as 50% for drugs metabolised 
primarily by CYP 450 isozymes. For oxcarbazepine and cabergoline, both classified 
as high extraction drugs, higher changes would have been predicted based on their 
estimated hepatic extraction than observed in clinical studies. These differences 
between the expected and observed changes in cirrhotic patients may be explained 
mainly by the metabolic pathway of the substances. Oxcarbazepine for example 
undergoes 10-keto reduction by cytosolic arylketone reductases to the monohydroxy 
derivative(293) and is not metabolized by cytochrome P450 isozymes that are known 
to be affected by liver cirrhosis. Similarly, also for cabergoline, the contribution of 
CYP-mediated metabolism is minimal.(280) 
Although pharmacokinetic data in patients with liver disease is available for 55 of the 
116 drugs studied, there is an information gap for a larger part of centrally acting 
drugs. Only few studies in patients with liver cirrhosis are available for antipsychotics, 
anti-parkinson drugs and most of the antidepressants, except for SSRIs and some 
newer antidepressants. In general, information about pharmacokinetic properties in 
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patients with liver disease is lacking especially for older drugs, while for newer drugs 
results from pharmacokinetic studies are often included in the product information. 
There appears to be an effort by the pharmaceutical companies to provide 
information about the pharmacokinetics of drugs in vulnerable patient groups such as 
patients with liver disease. Information about pharmacokinetics in patients with renal 
or hepatic disease as well as for elderly patients should be included in the product 
information for every new drug released on the market.  
Findings from clinical pharmacokinetic studies may sometimes be of limited value, as 
most of the studies were single dose trials, not reflecting exactly the situation in the 
every day practice. In contrast to single dose administration, a more accentuated 
accumulation of certain substances would be expected in patients with liver disease 
during long-term treatment. 
Clinical studies as well as the product information did often not provide precise dose 
recommendations for patients with liver disease, suggesting only dose reduction of a 
specific drug without quantifying the reduction. The combination of the results from 
pharmacokinetic studies with the estimates based on hepatic extraction showed often 
to be helpful to formulate more precise dose recommendations. However, 
prospective clinical trials testing the appropriateness of such dose recommendations 
are mostly lacking. 
For centrally acting drugs, not only dose adjustment based on pharmacokinetic 
properties is necessary, but also changes in pharmacodynamics should be 
considered. For example, cirrhotic patients have a greater cerebral sensitivity to a 
number of drugs acting on the central nervous system (CNS), e.g. benzodiazepines 
or antipsychotics.(7, 277) Although the mechanism underlying this hypersensitivity 
remains to be explained, there is evidence that it is not caused only by 
pharmacokinetic alterations. Patients with hepatic encephalopathy require special 
consideration, as benzodiazepines and/or drugs with anticholinergic properties may 
worsen cognitive function.(375, 396) Nevertheless, administration of 
benzodiazepines is indicated for treatment of alcohol withdrawal, anxiety or before 
endoscopic procedures or surgery in such patients. With the exception of flurazepam, 
midazolam and triazolam, benzodiazepines are all categorized as low extraction 
drugs. Since CYP-mediated metabolism is generally more affected by liver disease 
than glucuronidation,(1, 273) we consider lorazepam, oxazepam and temazepam as 
the benzodiazepines of choice for patients with liver cirrhosis. 
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Conclusion 
Dose recommendations which are based on the hepatic extraction and/or 
bioavailability of a drug are generally in a good agreement with the data from 
pharmacokinetic studies in patients with liver cirrhosis. Classification of drugs 
according to hepatic extraction is therefore a useful approach for dose adjustment in 
patients with liver cirrhosis, when appropriate clinical studies are lacking. For a larger 
part of centrally acting drugs, clinical pharmacokinetic studies and precise dose 
recommendations are not available. Pharmaceutical companies should be urged to 
provide precise dosage recommendations for new drugs and for critical drugs (e.g. 
drugs with a high hepatic extraction) already on the market. 
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Tables 
 
Table I. Categorisation of psychotropic drugs screened according to pharmacokinetic 
variables 
 
Category Level of hepatic 
extraction (%) 
Resulting oral bioavailability 
1 High (>60) Oral bioavailability is <40% in the case of complete 
intestinal absorption (or lower, if intestinal 
absorption is not complete) 
2 Intermediate 
(30-60) 
Oral bioavailability is 40-70% in the case of 
complete intestinal absorption (or lower, if intestinal 
absorption is not complete) 
3 Low (<30) Oral bioavailability is >70% in the case of complete 
intestinal absorption (or lower, if intestinal 
absorption is not complete). In this category, 
protein binding may be relevant: for drugs with high 
binding to albumin (>90%), hepatic clearance may 
increase 
4 Unknown Not known 
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Table II. Classification of liver injury according to Bénichou C.(287)  
 
Liver injury Characterisation 
Hepatocellular liver injury Isolated elevation of transaminases of 
hepatic origin or Ra ≥5. 
Cholestatic liver injury Isolated elevation of alkaline 
phosphatase of hepatic origin or R ≤2. 
Mixed liver injury Concomitant elevation of transaminases 
and alkaline phosphatase and 2 < R < 5. 
 
a )normalofitlimuppertimes(ephosphatasalkaline
)normalofitlimuppertimes(seotransferaminaalanineR =  
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Table III. Psychotropic drugs with Q0 ≥ 0.5 listed by hepatic extraction category 
 
Category Drugs 
 Antiepileptics 
1 Oxcarbazepine 
2 - 
3 Barbexaclone, carbamazepine, clonazepam, ethosuximide, lamotrigine, 
phenobarbital, phenytoin, primidone, tiagabine, valproate 
4 Methsuximide, sulthiame 
 Anti-parkinson drugs 
1 Biperiden, bromocriptine, cabergoline, dihydroergocryptine, entacapone, 
levodopa, pergolide, selegiline 
2 Ropinirole 
3 Procyclidine, tolcapone 
 
 Antipsychotics 
1 Chlorpromazine, chlorprothixene, fluphenazine, perphenazine, 
promazine, quetiapine 
2 Amisulpride, clozapine, flupenthixol, haloperidol, levomepromazine, 
olanzapine, risperidone, zuclopenthixol 
3 Aripiprazole, penfluridol, sertindole 
4 Clothiapine, pipamperone 
 Anxiolytics, sedatives and hypnotics 
1 Buspirone, clomethiazole, flurazepam, hydroxyzine, promethazine, 
zaleplon 
2 Diphenhydramine, midazolam, triazolam, zolpidem 
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3 Alprazolam, bromazepam, chlordiazepoxide, clobazam, clorazepate, 
diazepam, flunitrazepam, lorazepam, lormetazepam, meprobamate, 
methaqualone, nitrazepam, oxazepam, prazepam, temazepam, 
zopiclone 
4 Chloral hydrate, doxylamine, ketazolam 
 Antidepressants 
1 Bupropion, dibenzepin, doxepin, mianserin, sertraline 
2 Amitriptyline, clomipramine, escitalopram, fluvoxamine, imipramine, 
maprotiline, mirtazapine, moclobemide, nortriptyline, oxitriptan, 
paroxetine, trimipramine, venlafaxine 
3 Citalopram, fluoxetine, reboxetine, trazodone 
4 Melitracen, opipramol 
 Psychostimulants 
1 Methylphenidate, sibutramine 
2 - 
3 Amfepramone, modafinil 
 Anti-dementia drugs 
1 Rivastigmine 
2 - 
3 Donepezil, galantamine, memantine 
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Table IV. Most common dose-dependent adverse reactions of selected psychotropic 
drug classes(280, 282) 
 
Anti-Parkinson 
drugs 
Dopaminergic substances: nausea, vomiting, orthostatic 
hypotension, hallucination, agitation, confusion, dyskinesia 
Anticholinergics: dry mouth, blurred vision, constipation, 
tachycardia, urinary retention, hallucination, delirium 
Antipsychotics Adverse reaction profile depends on the specific receptor 
affinity:(330) 
Dopaminergic: extrapyramidal symptoms (especially typical 
antipsychotics), hyperprolactinemia 
Adrenergic: orthostatic hypotension 
Muscarinic: anticholinergic effects 
Histaminergic: sedation, weight gain 
Others: QT prolongation 
Anxiolytics, 
sedatives and 
hypontics 
Benzodiazepines: Somnolence, confusion, muscle 
weakness, ataxia, respiratory depression 
Benzodiazepine-like substances: somnolence, 
drowsiness, asthenia 
Antihistamines: anticholinergic effects, sedation 
Antidepressants Tricyclic antidepressants: anticholinergic effects, sedation, 
ECG changes, hypotension, tachycardia 
SSRIs:(331) nervousness, insomnia, diarrhea, nausea, 
tachycardia, serotonin syndrome 
Psychostimulants Restlessness, dizziness, insomnia, palpitation and/or 
tachycardia, hypertension, dry mouth, anorexia 
Anti-dementia Cholinesterase inhibitors: nausea, vomiting, diarrhea, 
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drugs bradycardia, hypotension  
Antiepileptics Barbiturates: sedation, drowsiness, ataxia, nystagmus, 
respiratory depression 
Hydantoin derivatives (phenytoin): acute symptoms: 
nystagmus, diplopia, ataxia, respiratory and circulatory 
depression 
Succinimide derivatives (ethosuximide, methsuximide): 
nausea, vomiting, drowsiness, dizziness, photophobia, 
ataxia, hiccup 
Benzodiazepines: see anxiolytics, sedatives and hypnotics 
Carboxamide derivatives (carbamazepine, 
oxcarbazepine): diplopia, nystagmus, ataxia, dizziness, 
nausea, vomiting, hyponatremia 
Fatty acid derivatives (valproate): somnolence, tremor, 
nausea, vomiting, hyperammonemia 
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Table V. Kinetic data, hepatic adverse effects, and dose recommendations in patients with liver disease for antidepressants, 
antipsychotics, anxiolytics, sedatives and hypnotics with high hepatic extraction available in Switzerland in 2006.  
 
Drug  Cata Kinetic parametersb, c, d Hepatic adverse 
effects 
Studies performed and dose recommendations 
Antidepressants 
 
Bupropion 1 Metabolism: Hydroxylation 
(CYP 2B6), reduction.(281) 
Q0: >0.95 
Vd: 28 l/kg 
t1/2: 21 h 
PB: 84% 
Clsys: 160 ml/min 
E: >0.9 
Rare: abnormal 
liver tests, 
jaundice, 
hepatitis.(280, 
362, 363) 
Studies: Half-life of hydroxybupropion was prolonged (32 h vs 21 h; 
p>0.05) in patients with alcoholic liver disease compared to healthy 
volunteers.(420) 
Product information: No significant difference in the pharmacokinetics 
between patients with mild to moderate liver cirrhosis and healthy 
controls. Cmax increased by 70%, half-life by 40% and AUC by 200% in 
patients with severe liver cirrhosis compared to healthy controls. Half-
life of metabolites prolonged about 2- to 4-fold. Contraindicated in 
patients with severe liver cirrhosis. Recommended daily dose for 
patients with mild to moderate liver disease 150mg. 
Personal Recommendation: According to pharmacokinetic data and 
clinical studies, start with lowest available dose (150mg/d). Adjust 
maintenance dose or dosage interval according to dose-dependent 
adverse effects. Because of expected massive increase in 
bioavailability, bupropion should better be avoided in patients with 
severe liver cirrhosis (Child C). 
Dibenzepin 1 Metabolism: N-
demethylation.(280) 
Q0: 1 
Vd: 4.2 l/kg 
t1/2: 5 h 
PB: 85% 
F: 25% 
 
Studies: No clinical studies available in patients with liver disease. 
Product information: Caution in patients with liver insufficiency. 
Personal Recommendation: According to pharmacokinetic data, initial 
doses should not exceed 25% of normal in patients with liver cirrhosis. 
Maintenance doses should be adjusted according to clinical effect and 
dose-dependent adverse reactions. 
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Doxepin 1 Metabolism: Demethylation, 
N-oxidation, hydroxylation, 
glucuronidation;(280, 282) 
Q0: 1 
Vd: 20 l/kg 
t1/2: 17 h 
PB: 95% 
F: 27% 
Clsys: 65 ml/min 
E: >0.9 
Rare: 
hyperbilirubinemia,
(280) cholestatic 
and/or 
hepatocellular liver 
injury.(286) 
Studies: No clinical studies available in patients with liver disease. 
Product information: Caution in patients with liver disease. Dose 
adjustment is recommended in patients with severe liver disease (no 
specification). 
Personal Recommendation: Based on the pharmacokinetic data, start 
with lowest possible dose (10mg/d). Adjust maintenance dose 
according to clinical effect and dose-dependent adverse reactions. 
Mianserin 1 Metabolism: CYP 2D6,(323) 
N-oxidation, hydroxylation, 
N-demethylation(282) 
Q0: 0.95 
Vd: 15.7 l/kg 
t1/2: 33 h 
PB: 95% 
F: 25% 
Clsys: 19.1 ml/min i.v. 
(higher Clsys after p.o. 
administration observed) 
E: 0.34 
Cases: mixed 
hepatic injury, 
cholestatic liver 
disease,(358) 
elevated liver 
enzymes.(280) 
Studies: No clinical studies available in patients with liver disease. 
Product information: Mianserin is contraindicated in patients with 
severe liver disease. 
Personal Recommendation: According to pharmacokinetic data, start 
with lowest possible dose (15mg/d). Adjust maintenance dose 
according to dose-dependent adverse reactions. 
Sertraline 1 Metabolism: N-
demethylation (CYP 2D6, 
2C9, 2B6, 2C19, 3A4), 
hydroxylation, oxidative 
deamination, N-carbamoyl 
glucuronidation.(320) 
Q0: 1 
Vd: 25 l/kg 
t1/2: 23 h 
PB: 98% 
Rare: 
hepatocellular 
injury.(286)  
Case reports: liver 
failure.(280) 
Studies: AUC increased 4 times, half-life 2.5 times and cmax 1.7 times 
in patients with liver cirrhosis after intake of 100mg sertraline as a 
single oral dose.(414) It was recommended to start with 50mg 
sertraline per day and increase dosage only after 15 days, if 
necessary. 
Product information: Start treatment in patients with liver cirrhosis Child 
Pugh A and B with 50% of normal initial dose. Contraindicated in 
patients with liver cirrhosis Child Pugh C. 
Personal Recommendation: According to pharmacokinetic data and 
product information, it is recommended to start with 50% of normal 
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Clsys: 96 ml/min 
E: >0.9 
dose (25mg/d). Adjust maintenance dose according to dose-
dependent adverse reactions. Do not up-titrate the dose before 2 
weeks after treatment beginning or dose adjustment. 
Antipsychotics 
 
Chlorpromazine 1 Metabolism: Hydroxylation 
(CYP 2D6, 1A2), N-
demethylation, N-oxidation, 
deamination, 
sulfoxidation,(282, 299) 
partial biliary excretion(280) 
Q0: 1 
Vd: 22 l/kg 
t1/2: 30 h 
PB: 95% 
F: 32% 
Clsys: 36.1 ml/min 
E: 0.67 
Risk of hepatic 
encephalopathy in 
patients with liver 
cirrhosis.(344) 
Sporadic: 
cholestatic liver 
injury.(286) 
Studies: Changes in EEG associated with drowsiness and increased 
sensitivity in patients with liver cirrhosis, particularly in patients with 
previous history of encephalopathy.(344, 375) Should be avoided in 
patients with liver cirrhosis due to the risk of hepatic 
encephalopathy.(344) 
Product information: Contraindicated in patients with cholestatic liver 
injury. 
Personal Recommendation: According to pharmacokinetic data, start 
with 25-50% of normal initial dose. Adjust maintenance dose according 
to dose-dependent adverse effects. 
Chlorprothixene 1 Metabolism: Sulfoxidation, 
N-demethylation, 
hydroxylation, N-
oxidation(280) 
Q0: 0.95 
Vd: 15.5 l/kg 
t1/2: 12 h 
PB: 99% 
F: 12% 
Clsys: 72 ml/min 
E: >0.9 
Sporadic: 
cholestatic liver 
injury.(286) 
Studies: No clinical studies available in patients with liver disease. 
Product information: Caution in patients with severe liver disease. 
Dose adjustment recommended (no specification). 
Personal Recommendation: According to pharmacokinetic data, start 
with lowest possible dose (5mg). Adjust maintenance dose according 
to dose-dependent adverse reactions.  
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Fluphenazine 1 Metabolism: Hydroxylation, 
glucuronidation, 
sulfoxidation, 
demethylation,(288) biliary 
excretion, enterohepatic 
circulation.(280) 
Q0: 1 
Vd: 25 l/kg 
t1/2: 16.4 h 
PB: 90% 
F: 2.7% (oral) 
Clsys: 42 ml/min 
E: 0.78 
Rare: cholestatic 
liver injury.(286) 
Studies: No clinical studies available in patients with liver disease. 
Product information: In Switzerland only slow-release preparation for 
intramuscular injection available. Dose adjustment recommended in 
patients with impaired liver function. Contraindicated in patients with 
liver injury. 
Personal Recommendation: Only a slow-release preparation for 
intramuscular injection is available in Switzerland. In patients with liver 
disease alternatives should be used, since there are no clinical 
studies. 
Perphenazine 1 Metabolism: CYP 2D6.(283) 
Hydroxylation, 
demethylation, 
sulfoxidation, 
glucuronidation.(282) 
Enterohepatic 
circulation.(280) 
Q0: 1 
Vd: 20 l/kg 
t1/2: 9.5 h 
PB: 90% 
F: 20% 
Clsys: 107 ml/min 
E: >0.9 
Sporadic: 
cholestatic liver 
injury.(286) 
Studies: No clinical studies available in patients with liver disease. 
Product information: No recommendations provided. 
Personal Recommendation: According to pharmacokinetic data, start 
with the lowest possible dose (2mg) and adjust maintenance dose 
according to clinical effect and dose-dependent adverse reactions. 
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Promazine 1 Metabolism: Hydroxylation, 
N-oxidation, N-
demethylation (CYP 1A2, 
2C19), sulfoxidation (CYP 
1A2, 3A4).(282, 300)  
Q0: 1 
t1/2: 15 h (variable) 
PB: 92% 
F: 16% 
Phenothiazines 
may cause 
intrahepatic 
cholestasis.(282) 
Studies: In cirrhotic patients (Child A and B) total plasma clearance 
decreased by 76%, elimination half-life was 2 times, AUC 2.9 times 
higher compared to healthy subjects.(377) No change in 
pharmacokinetics during acute phase of viral hepatitis B, but more 
adverse effects observed (sedation, postural hypotension, 
dizziness).(376) Adjust dosage in cirrhotic patients (no specific dosage 
recommendation).(377) 
Product information: Caution in patients with liver disease.(280) Use 
not recommended in patients with liver disease because 
phenothiazines may cause intrahepatic cholestasis.(282) 
Personal Recommendation: According to the pharmacokinetic 
parameters, start with 25% of normal initial dose. Adjust dosage 
according to dose-dependent adverse reactions. 
 
 
Quetiapine 1 Metabolism: Dealkylation, 
hydroxylation (CYP 3A4, 
2D6 [minor]), sulfoxidation, 
glucuronidation.(303) 
Q0: 0.95 
Vd: 10 l/kg 
t1/2: 6 h 
PB: 83% 
F: 9% 
Clsys: 79.8 ml/min 
E: >0.9 
Rare: jaundice, 
transient and 
reversible 
elevations in 
serum 
transaminase 
(primarily 
ALT).(280, 283) 
Case report: 
subfulminant liver 
failure.(347) 
Studies: Compared to healthy controls clearance decreased by 25% in 
patients with liver cirrhosis, AUC and cmax increased by 40% and 
elimination half-life prolonged by 77%.(379) The authors concluded 
that patients with hepatic liver cirrhosis may be given 25mg quetiapine 
as starting dose, and dose escalation should be conducted with 
caution. 
Product information: Recommendations based on the study from 
Thyrum PT et al. (2000) conducted by Astra Zeneca. Start with 25mg 
quetiapine on the first day. Up-titrate carefully in increments of 25-
50mg/d to an effective dose, depending on clinical response and dose-
dependent adverse reactions. 
Personal Recommendation: According to pharmacokinetic data and 
clinical study, start with 25mg and up-titrate carefully according to 
clinical effect and dose-dependent adverse reactions. 
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Anxiolytics, hypnotics, sedatives 
 
Buspirone 1 Metabolism: CYP 3A,(280) 
oxidative dealkylation, 
hydroxylation, 
glucuronidation.(282) 
Q0: 1 
Vd: 5 l/kg 
t1/2: 2.4 h 
PB: 95% 
F: 4% 
Clsys: 92.5 ml/min 
E: >0.9 
 
Studies: Cmax about 16 times higher in patients with liver cirrhosis than 
in controls. Elimination half-life in cirrhotics about twice that of normal 
subjects.(392) Should be used with caution in patients with liver 
disease.(392) Due to the high intra- and inter-subject variability of the 
plasma buspirone concentration data in patients with liver cirrhosis, 
dosing recommendations cannot be made.(393) 
Product information: Contraindicated in patients with liver disease. 
Personal Recommendation: According to pharmacokinetic data start 
with lowest possible dose (5mg) due to variable bioavailability in 
patients with portosystemic shunts. Adjust maintenance dose 
according to dose-dependent adverse reactions. Dose interval may be 
reduced from 3 times to 1-2 times daily. 
Clomethiazole 1 Metabolism: CYP 2A6, 
3A4/5, 2B6, 1A1, 
2C19.(280) 
Q0: 0.95 
Vd: 9 l/kg 
t1/2: 6 h 
PB: 65% 
F: 10% 
Clsys: 100 ml/min 
E: >0.9 
Elevation of 
transaminases. 
Rare: jaundice, 
cholestatic 
hepatitis.(280) 
Studies: Clearance decreased by 30%, bioavailability 10 times higher 
in patients with advanced alcoholic liver cirrhosis compared to healthy 
subjects.(44) Dose reduction recommended (no specification).(44) 
After continuous infusion of clomethiazole systemic clearance 
decreased by 50% and half-life prolonged by 90% in patients with liver 
cirrhosis (Child B and C).(408) No statistically significant difference 
between subjects with mild liver impairment and healthy controls. 
Product information: Avoid in patients with severe liver disease. 
Clomethiazole should not be given to alcoholics with liver cirrhosis, 
because of fatal respiratory depression in combination with alcohol. 
Personal Recommendation: Oral administration should be avoided in 
patients with liver cirrhosis since bioavailability is unpredictable. Start 
intravenous therapy with 25-50% of normal dose and adjust dose 
according to dose-dependent adverse effects. Lorazepam, oxazepam 
and temazepam are better alternatives. 
Flurazepam 1 Metabolism: N-
desalkylation, 
hydroxylation(282) 
Rare: cholestatic 
liver injury.(286) 
Studies: No clinical studies available in patients with liver disease. 
Product information: Flurazepam should be used with caution in 
patients with impaired hepatic function. 
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Q0: 1 
Vd: 3.4 l/kg 
t1/2: 2 h 
PB: 95% 
F: 30% 
Personal Recommendation: Flurazepam is not an ideal hypnotic in 
patients with liver disease. Lorazepam, oxazepam, and temazepam 
are the benzodiazepines of choice for patients with liver disease. 
Hydroxyzine 1 Metabolism: Hepatic 
metabolism to cetirizine 
(active),(307) 70% of the 
dose eliminated by biliary 
excretion.(280) 
Q0: 1 
Vd: 16 l/kg 
t1/2: 20 h 
Clsys: 41.1 ml/min 
E: 0.76 
Rare: hepatic or 
cholestatic 
jaundice.(280) 
Studies: Prolonged elimination half-life (36.6h), decreased clearance 
(36.3 L/h), and increased volume of distribution (23 L/kg) in patients 
with primary biliary cirrhosis.(307) Increase normal dosage interval of 
2-3 times daily to once per 24 hours or less.(307) 
Product information: In patients with liver cirrhosis clearance was 
reduced by about 33%. Elimination half-life was increased to 37h and 
serum concentration of cetirizine were higher compared to healthy 
individuals. Reduce dosage in patients with moderate liver disease. 
Contraindicated in patients with severe liver insufficiency. 
Personal Recommendation: According to the pharmacokinetic data, 
start with 50% of normal initial dose (12.5mg). Adjust maintenance 
dose according to dose-dependent adverse reactions. 
Promethazine 1 Metabolism: Sulfoxidation, 
N-dealkylation (CYP 2D6), 
biliary excretion.(282) 
Q0: 1 
Vd: 14 l/kg 
t1/2: 12 h 
PB: 85% 
F: 25% 
Clsys: 68 ml/min 
E: >0.9 
jaundice(283) Studies: No clinical studies available in patients with liver disease. 
Product information: Caution in patients with liver impairment.(281) 
Personal Recommendation: In Switzerland only a combination of 
promethazine with carbocisteine as expectorant is available. 
Promethazine is contained at lower dose compared to a 
monosubstance preparation available in the USA, therefore no 
recommendation for patients with liver disease are made. 
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Zaleplon 1 Metabolism: Aldehyde 
oxidase, desalkylation (CYP 
3A4), followed by 
glucuronidation.(280) 
Q0: 1 
Vd: 1.4 l/kg 
t1/2: 1 h 
PB: 60% 
F: 31% 
Clsys: 70 ml/min 
E: >0.9 
 
Studies: No clinical studies available in patients with liver disease. 
Product information: Oral clearance reduced by 70% and 87% in 
compensated and decompensated cirrhotic patients, respectively, up 
to 4-fold increase in cmax and up to 7-fold increase in AUC in 
comparison with healthy subjects.(281) Contraindicated in patients 
with liver insufficiency.(280) 
Personal Recommendation: According to pharmacokinetic data and 
product information, start with lowest possible dose in patients with 
mild to moderate hepatic insufficiency (5mg). Adjust dosage according 
to dose-dependent adverse reactions. Zaleplon should be avoided in 
patients with severe hepatic impairment. Better alternatives are 
available: lorazepam, oxazepam and temazepam. 
 
a Cat = drug category. Drugs were categorized as follows: Category 1: high hepatic extraction (E >60%, F <40%), category 2: 
intermediate hepatic extraction (E = 30-60%, F = 40-70%), category 3: low hepatic extraction (E <30%, F >70%), category 4: hepatic 
extraction not known. 
b The fraction metabolised or excreted by bile (1-Q0: fraction excreted unchanged by the kidney). 
c For calculation, bodyweight was assumed to be 70kg. 
d Calculated as described in equation 2 of the main article. 
ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; AUC = area under the 
concentration-time curve; Cat = drug category; Clsys = systemic clearance; cmax = maximum concentration; CYP = cytochrome P450; 
E = hepatic extraction; F = bioavailability; γGT = gamma-glutamyl transpeptidase; PB = fraction bound to proteins; Q0 = extrarenal 
dose fraction; t1/2 = dominant half-life; Vd = volume of distribution
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7 General Discussion and Outlook 
 
 
Adaptation of the dosage of drugs in patients with liver disease is more difficult than 
in patients with renal disease, since there is no endogenous marker for hepatic 
clearance, which could be used as a guide for dosing of drugs. 
In this thesis strategies for dosage adaptation of drugs in patients with liver disease 
were defined.  
 
In chapter 3 the kinetic and dynamic changes of drugs in patients with liver disease 
were discussed and general dosage recommendations given. However, these 
predictions for dose adaptation remain general and cannot replace accurate clinical 
monitoring of patients with liver disease treated with drugs owing a narrow 
therapeutic range. 
 
In chapter 4, an interactive e-learning course about dose adaptation in liver disease 
was developped for the Swiss Virtual Campus.  
 
In chapter 6.1. and 6.2., the antineoplastic drugs and psychotropic agents marketed 
in Switzerland were classified according to their bioavailability / hepatic extraction in 
order to predict their kinetic behaviour in patients with decreased liver function. This 
prediction was compared with kinetic studies carried out with these drugs in patients 
with liver disease.  
Both studies showed that for most of the drugs studied, dosage recommendations 
are not available for patients with liver insufficiency. This is due to the absence of 
published data about hepatic extraction (E) (which is essential to help dosing in 
patients with liver disease) and the scarcity of performed clinical studies in patients 
with liver disease.  
However, dose recommendations which are based on the hepatic extraction and / or 
bioavailability of a drug are generally in a good agreement with the data from 
pharmacokinetic studies in patients with liver cirrhosis. Classification of drugs 
according to hepatic extraction is therefore a useful approach for dose adjustment in 
patients with liver cirrhosis, when appropriate clinical studies are lacking.  
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Therefore, individual dosage recommendations were provided for each drug with 
relevant hepatic metabolism based on the results of the literature research and / or 
the general principles of dose adaptation in liver disease as discussed in chapter 3. 
 
For a larger part of drugs, we consider that there are currently not enough data for 
the safe use in patients with liver disease. Pharmaceutical companies should be 
urged to provide kinetic data (especially hepatic extraction) needed for the 
classification of such drugs. For drugs with primarily hepatic metabolism, kinetic 
studies should be performed in patients with impaired liver function, thus allowing to 
give quantitative advice for dose adaptation. 
 
The collected data and results for antineoplastic and psychotropic agents will be 
expanded by the antiinfective agents (about 160 drugs) and a further group of 
chosen therapeutic classes frequently applied to patients with liver disease (about 
200 drugs).  
The data content of this collected work including more than 540 drugs could be 
further proceeded to a reference book or electronic database as a useful tool for 
dosage in patients with liver disease. 
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• Online course:  
Schlatter C, Krähenbühl S: Dosisanpassung bei Leberinsuffizienz. Bern: Swiss 
Virtual Campus, 2004.  
„SVC - Dosisanpassung bei Leberinsuffizienz“ (PDF file) 
 
• Online course:  
Schlatter C, Krähenbühl S: Dosisanpassung von Arzneistoffen bei Patienten 
mit Leberinsuffizienz. In: Online Academy. Ausgabe Nr. 3.1. Zürich: PNN 
pharma nation network, 2004.  
„Online Academy – Dosisanpassung bei Leberinsuffizienz“ (PDF file) 
 
• Schlatter C, Krähenbühl S: Dosisanpassung bei Leberkrankheiten. In: 
Grundlagen der Arzneimitteltherapie. Basel: Documed, 2005.  
„Documed – Dosisanpassung bei Lebererkrankungen“ (PDF file) 
 
• Complete table of all studied antineoplastic agents:  
„Psychotropic Drugs – Complete List” (PDF file) 
 
• Complete table of all studied psychotropic drugs: 
„Antineoplastic Drugs – Complete List” (PDF file) 
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